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ABSTRACT
SELF-EMULSIFIED NANOEMULSION AS PERMEATION ENHANCER AND ITS
APPLICATION FOR INTRANASAL DELIVERY OF INSULIN
Kanyaphat Bunchongprasert

This study aimed to investigate the permeation enhancing property and safety of
self-emulsified nanoemulsion (SEN) and use these findings to enhance insulin absorption
through the nasal route.
The first part of the project was to identify the factors affecting cytotoxicity and
permeation enhancement of SEN on Madin-Darby Canine Kidney (MDCK) cells, a
widely used paracellular model. Twenty-six fatty acid esters (FAEs) commonly used in
SEN were investigated. Among the FAEs (mono-, di-, and triesters), fatty acid
monoesters (FAME) are the main excipient causing cytotoxicity and opening tight
junction. The cytotoxicity of FAME in SEN was reduced with the presence of
triglycerides, the increase in droplet size, and the higher intermolecular interaction within
the lipid droplets.
Then, the SENs consisted of various FAMEs, medium-chain triglyceride and
Kolliphor®RH40 (1:1:2) were evaluated for their capability to enhance insulin across
human airway epithelium cell (Calu-3) monolayer. The SENs containing medium-chain
monoglyceride, G8/10MD (C8/C10 mono/diglycerides) showed the greatest permeability
enhancement on insulin across the Calu-3 monolayer. The opening of the tight junction
was reversible. Also, the SEN containing G8/10MD (SEN-G8/10MD) could prevent the
fibril formation of insulin.

Therefore, SEN-G8/10MD was selected for the ex vivo and in vivo studies. SENG8/10MD (0.8-30%) had droplet size of 31±9 nm, polydispersity index of 0.065±0.031
and zeta potential of -1.86±0.74 mV. The permeability of insulin across the ex vivo
bovine nasal mucosa was significantly (p<0.05) increased by SEN-G8/10MD at 20% of
the preconcentrate with a minimum nasociliotoxicity observed. In vivo study in
streptozotocin-induced diabetic rats showed that as compared to subcutaneous injection,
the relative pharmacodynamics availability achieved by SEN-G8/10MD at 20%, 10%,
and 5% of the preconcentrate were 79.5%, 58.4% and 42.0%, respectively, significantly
higher (p<0.05) than the 1.4% by the solution form. The three SENs also achieved the
relative bioavailability of 37.9%, 19.3% and 8.8%, respectively, and the first two were
significantly (p<0.05) higher than the 4.0% by the solution form. The SENs did not cause
noticeable toxicity on the rats’ nasal epithelium.
In conclusion, the SEN containing G8/10MD has a potential to deliver insulin
across the nasal route.
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INTRODUCTION
Self-emulsified nanoemulsion (SEN) spontaneously forms upon the dilution of a
formulated preconcentrate, a combination of surfactant(s) and lipid(s) with or without
cosolvents. SEN has been successfully adopted for some lipophilic drugs to enhance their
absorption. For the main issue hindering lipophilic drugs from absorption is the
extremely low aqueous solubility of these drugs. But these drugs can have significantly
increased solubility in SEN due to a large amount of lipids and surfactants present in the
formulation. Once they are in the solution form, these lipophilic drug molecules can
easily diffuse through the absorption membrane via the transcellular route. However, it is
a different case when dealing with hydrophilic drugs such as peptide/protein drugs. These
drugs are usually poorly absorbed because they cannot diffuse through the absorption
membrane via transcellular route for two reasons: the cell membrane is lipophilic and the
drug molecular size usually is too large. It is well known that the main absorption route
for these drugs is paracellular route, and the tight junction between the cells is the main
obstruction for the paracellular absorption.
How to open the tight junction and enhance the paracellular absorption have been
extensively investigated for several decades. Many studies have demonstrated that most
agents such as certain surfactants, bile salts, etc. which are able to open the tight junction
exhibit certain toxicity on the cell membrane. The ideal case is that the agent opens the
tight junction with minimum toxicity and the opening process is reversible.
As early as in 2008, as the pilot study, our laboratory published several research
papers on using SEN to deliver a model protein drug, -lactamase1-3. Since then, it has
been seen in many publications from other research institutes on using SEN for
1

hydrophilic drugs with improved absorption. In recent years, our laboratory developed
another SEN formulation for insulin intranasal delivery with 69% bioavailability relative
to subcutaneous injection in rats. It can be inferred from these enhanced absorptions that
the SENs could open the tight junction and enable these large and hydrophilic molecules
to diffuse through the paracellular route, although several other mechanisms have also
been proposed for the enhanced absorption.
Then come the questions: 1) which ingredients of the SEN formulation are
effective in opening tight junction? 2) What is the safe concentration with minimum or
acceptable toxicity? 3) Can the opening be reversed? and 4) How are these activities
affected by the other ingredients in SEN and by the SEN properties such as droplet sizes?
Literature search indicates that there lack of systemic investigations on these issues.
Therefore, the current project aims to answer these questions, particularly with the
focus on fatty acid ester derivatives as the lipid and surfactants components of SEN, and
also, based on these answers, to formulate a SEN for insulin, and further, to test its
toxicity and absorption enhancement via in vitro, ex vivo and in vivo studies.
Factors Affecting Cytotoxicity and Permeation Enhancement of SENs
Most of the lipids and surfactants used to formulate SEN are amphiphilic, which
comprises fatty acid(s) esterified with different hydrophilic head groups, called fatty acid
ester derivatives (FAE). Literature indicates that many FAEs exhibit cytotoxic and
permeation enhancing activities by disrupting the tight junctions to enhance paracellular
transport 4, 5. Some of FAE structures including the numbers of chains and their chain
length were reported affecting these activities. For example, Aungst et al. stated that
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medium-chain triglycerides as permeation enhancers were much less effective than
mono- and diglycerides4. Ujhelyi et al. showed that the permeability enhancement on
lucifer yellow across the paracellular route of human colon carcinoma (Caco-2) by
Tween®20 (C12) was higher than Tween®60 (C16) ≈ Tween®80 (C18:1, the number after
colon indicates the number of double bonds), showing that the permeation enhancing
effect of Tween® (FAE of PEGylated sorbitan) decreased with the increase in their chain
length and also affected by the double bond6.
However, Pabla et al. reported that the permeation enhancing effect of fatty acids
increased with the increase in their chain length7, which was opposite to the Tween®s.
The difference between fatty acids and FAEs is that the latter have larger hydrophilic
head groups making them able to self-assemble to form micelles at the concentration
higher than their critical micelle concentration (CMC)8. This indicates that the
hydrophilic head group is another important structural factor of FAEs, and the micelle or
droplet formation may affect FAE to interact with the cell membranes.
In addition to the structural factors of FAEs on permeation enhancement of SEN,
many factors have not been thoroughly investigated for the application of SEN for
hydrophilic drugs such as the effect of droplet size, the interaction among excipients, etc.
Therefore, the initial objective of the present study is to investigate factors affecting
cytotoxicity and tight junction opening of SEN including 1) the numbers of fatty acid
chains, 2) the presence of triglycerides, 3) the droplet size of SEN, and 4) the structures
of FAEs, which are addressed in Chapter 1, where twenty-six FAEs with six hydrophilic
head groups (propylene glycol, glycerol, sorbitan, polyethylene glycol, sucrose, and

3

PEGylated sorbitan) and various chain structures (number of chains, chain length, and
number of double bonds) are investigated.
Nasal Delivery of Insulin by SEN
Insulin is a hydrophilic two-chain protein with 51 amino acids, three disulfide
bonds, and a molecular weight of 5.8 kDa. As the result, there are various challenges for
insulin to be delivered across non-invasive routes e.g. poor absorption across the
lipophilic epithelium, susceptibility to proteolytic enzymes, and disulfide reductase, etc.
Due to these challenges, the delivery of insulin remains as invasive dosage forms and a
powder inhalation (Afrezza®) which causes potential side effects reducing patient
compliance. Therefore, it is imperative to develop a safe and effective non-invasive
delivery of insulin.
Among non-invasive routes, the intranasal (i.n.) route has a great potential for
insulin delivery such as the thinnest epithelium (50 µm), abundant vasculature structure,
low enzymatic activity as compared to the rectal and intestinal routes, and avoiding firstpass metabolism 9, 10. However, the permeability of insulin across the nasal epithelium is
still low. The bioavailability of insulin solution following nasal administration to humans
was below 1% 11. The mucociliary clearance also limits the retention time of the
formulation on the nasal epithelium for about 15-20 min 12 and the ideal delivery volume
per adult nostril is limited to about 0.2-0.3 mL 13, 14.
A literature review shows that more than 50% of research articles have used the
permeation enhancers to improve the bioavailability of i.n. insulin. However, many
enhancers can cause damage to the nasal mucosa 10, 15, 16. SEN has been reported for its
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safety and efficacy to enhance the bioavailability of many drugs through oral routes. But
in addition to our previous studies on SEN for i.n. delivery of insulin, there is only one
publication on SEN to deliver insulin by i.n. route reported by Sintov et al., showing a
relative bioavailability of 21.5% from a w/o SEN consisted of 20% of water and 80% of
other lipid excipients including surfactants, etc. 17. Such a high percentage of the lipid
phase may cause several problems after nasal delivery, and the limited volume of water
may not provide sufficient insulin dose for a human. It can be seen that the application of
SEN on the nasal delivery of insulin has not been thoroughly studied.
Therefore, the SEN developed in Chapter 1 is further evaluated for its efficacy
and safety in delivering insulin through i.n. route by the means of in vitro cell culture, ex
vivo bovine nasal mucosa, and in vivo diabetic rats, which are addressed in Chapters 2, 3,
and 4, respectively.

5

RESEARCH OBJECTIVES
The objective of the present study is to investigate the permeation enhancing
property and safety of SEN, particularly the FAEs when formulated in SEN, and use
these findings to enhance insulin absorption through the nasal route.
The specific objectives are as following:
I.

to identify the factors affecting cytotoxicity and permeation enhancement of
SEN, particularly the FAEs when formulated in SEN; and develop a SEN for
insulin;

II.

to evaluate the efficacy and toxicity of the developed SEN for the transport of
insulin across cell monolayer in vitro;

III.

to investigate the efficacy and toxicity of the developed SEN for the transport
of insulin across bovine nasal mucosa ex vivo;

IV.

to study the efficacy and toxicity of the developed SEN for i.n. delivery of
insulin in streptozotocin-induced diabetic rats.
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CHAPTER 1
FACTORS AFFECTING CYTOTOXICITY AND PERMEATION
ENHANCEMENT OF SEN
In this present study, twenty-six FAEs (Table 1) with six hydrophilic head groups
including propylene glycol, glycerol, sorbitan, polyethylene glycol, sucrose, and
PEGylated sorbitan (Table 2) and various chain structures (number of chains, chain
length, and number of double bonds) were investigated for their cytotoxic and permeation
enhancing effects of SEN formulations. Madin-Darby Canine Kidney (MDCK) cell line
was used as the cell culture model since it exhibits tight junctions and has been widely
used as a paracellular model with time-efficiency advantage18-24.
1.1 Materials
Captex®8000, Captex®1000, Captex®100, Capmul®PG12 EP/NF, Capmul®MCM
C8, Capmul®MCM EP/NF, Capmul®808G EP/NF, and Capmul®GMO 50 EP/NF were
kindly gifted by Abitec Corporation (Janesville, WI, USA). Soybean oil, Span®20, and
Span®80 were purchased from Spectrum® Pharmaceuticals (Irvine, CA, USA).
Kolliphor®EL and Kolliphor®HS15 were kindly gifted from BASF (Tarrytown, NY,
USA). Labrafac™PG, Capryol™90, GELEOL™, PECEOL™, Maisine®CC, and
Labrasol®ALF were kindly gifted from Gattefossé (Paramus, NJ, USA). Sucrose Laurate
was kindly gifted from Mutchler Inc. (Lakewood, OH, USA). Kolliphor®RH40 and
Tween®80 were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tween®20 and
Dimethyl sulfoxide (DMSO) were purchased from VWR (West Chester, PA, USA).
Tween®85 and 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazoliumbromide (MTT) were
purchased from Thermofisher Acros Organics (Morris Plains, NJ, USA). Propylene
7

glycol monopalmitate and monostearate, and propylene glycol monostearate were
purchased from TCI America (Portland, OR, USA)
MDCK (NBL-2) cell line was purchased from ATCC® (Rockville, MD, USA).
Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s Phosphate-Buffer Saline, and
penicillin-streptomycin solution were purchased from Hyclone (Logan, UT, USA). Fetal
Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA,
USA). Mannitol, D-[1-14C], with 56.8 mCi/mmol, and Ultima Gold Scintillation cocktail
were purchased from PerkinElmer (Boston, MA, USA). Trypsin (0.05%) with 0.53 mM
ethylenediaminetetra acetic acid (EDTA) was purchased from Mediatech Inc. (Manassas,
VA, USA).
1.2 Methods
1.2.1 Preparation and Characterization of SENs
Table 1 shows the studied fatty acid esters (FAEs) and their abbreviations. The
solid, semi-solid, and highly viscous excipients including SPEG18:1T, Kolliphor®RH40,
G8M, G18:1/18:2MD, S18:1M, Kolliphor®HS15, PG16/18M, PG18M, and G16/18M
were melted at the possible lowest temperature for weighing.
Preconcentrates were specially formulated to investigate the effect of the numbers
of fatty acid chains in SEN on cytotoxicity (Table 3), the effect of triglyceride in SEN
and droplet sizes of SEN on cytotoxicity (Table 4), and the effect of the structure of fatty
acid monoester (FAME) in SEN on cytotoxicity and tight junctions (Table 5). The
preconcentrates were shaken in a MaxQ™4000 Orbital Shaker (Thermo Scientific™,
MA, USA) for three hours (300 rpm, 50ºC), except the preconcentrate containing
G16/18M was shaken at 65ºC. The preconcentrates were diluted with sterile DMEM to
form SENs at various concentrations. The preparation was done under aseptic conditions
8

and the SENs were freshly prepared for each experiment. The droplet size of the SENs
was measured by a Zetasizer® Nano ZS (Malvern Instrument Inc., MA, USA).

9

Table 1 Major compositions of fatty acid esters, their abbreviations, and HLB values.

Chemical Name

Commercial
Name

Major
Abbreviations
Compositions

HLB

Fatty Acid Tri-esters
Glyceryl Tricaprylate

Captex®8000

C8 Triesters

G8T

≤1

Glyceryl Tricaprate

Captex®1000

C10 Triesters

G10T

≤1

Long-chain
Triglycerides

Soybean oil

C18:1/C18:2
Triestersa

G18:1/18:2T

≤1

PEG-20 Sorbitan
Trioleate

Tween®85

C18:1
Triesters

SPEG18:1T

11

PEG-35 Castor Oil
(Hydroxyricinoleate)

Kolliphor®EL

Hydroxy
C18:1
Triesters

-

13

PEG-40
Hydrogenated Castor
Oil (Hydroxystearate)

Kolliphor®
RH40

Hydroxy C18
Triesters

-

15

PG8/10D

1

Fatty Acid Di-and Monoester
Fatty Acid Ester of Propylene Glycol (PG)
PG
C8/C10
Labrafac™PG
Dicaprylate/dicaprate
Diesters
PG Dicaprate

Captex®100

C10 Diesters

PG10D

≤1

PG Monocaprylate
(Type II)

Capryol™90

C8
Monoesterb

PG8M

5c

C12
Monoester

PG12M

4-6d

C16/C18
Monoester

PG16/18M

3-4

PG Monolaurate
(Type II)
PG Monopalmitate
and Monostearate

Capmul®
PG12 EP/NF
Propylene
Glycol
Monopalmitate/
Monostearate
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Propylene
PG Monostearate
Glycol
Monostearate
Fatty Acid Ester of Glycerol (G)
Glyceryl
Capmul®MCM
Monocaprylate (Type
C8
I)
Glyceryl
Capmul®MCM
Monocaprylate/Mono
EP/NF
caprate (Type I)
Glyceryl
Capmul®808G
Monocaprylate
EP/NF
(Type II)
Glyceryl
GELEOL™
Monostearate

C18
Monoester

PG18M

3-4

C8 Mono/diesters

G8MD

6-7d

C8/C10
Mono/diesters

G8/10MD

5-6d

C8 Monoester

G8M

6-7d

C16/C18
Monoester

G16/18M

3c
1c

Glyceryl Monooleate

PECEOL™

C18:1
Monoester

G18:1M

Glyceryl Monooleate

Capmul®GMO
50 EP/NF

C18:1/C18:2
Mono-/diester

G18:1/18:2MD

Glyceryl
Maisine®CC
Monolinoleate
Fatty Acid Ester of Sorbitan (S)

C18:2 Mono/diester

G18:2MD

1c

Sorbitan Monolaurate Span®20

C12
Monoester

S12M

8

C18:1
Monoester
Fatty Acid Ester of Polyethylene Glycol (PEG)
PEG-8
C8/C10
®
Caprylic/Capric
Labrasol ALF
MonoGlycerides
/Diesters
Hydroxy C18
PEG-15
Kolliphor®HS1
MonoHydroxystearate
5
/Diesters
Fatty Acid Ester of Sucrose (SC)
C12
Sucrose Monolaurate Sucrose Laurate
Monoester
Fatty Acid Ester of Sorbitan-PEG (SPEG)
Sorbitan Monooleate

PEG-20 Sorbitan
Monolaurate

Span®80

Tween®20

C12
Monoester

11

3-4d

S18:1M

4.3

PEG8/10MD

12c

-

15

SC12M

16

SPEG12M

16.7

PEG-20 Sorbitan
C18:1
Tween®80
SPEG18:1M
15
Monooleate
Monoester
a
: the number after the colon indicates the number of double bonds; b: Primarily contains
monoester, but also contains a certain amount of di- and tri-esters; c: reported by
Gattefossé; d: reported by Abitec
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Table 2 Structure of hydrophilic functional group of fatty acid esters.

Chemical name

Structure

Propylene Glycol (PG)

Glycerol (G)

Sorbitan (S)

Polyethylene Glycol
(PEG)

Sucrose (SC)

PEGylated Sorbitan
(SPEG;
Polyoxyethylene
sorbitan)
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Table 3 SEN formulations for the study of effect of the numbers of fatty acid chains in
SEN on cytotoxicity (mean ± SD, n =3).
Fatty Acid Esters (FAE)

Droplet Sizea

Polydispersity Index

(nm)

FAE and Kolliphor®RH40 at 1:4 (w/w)

a

G8T

27 ± 6

0.055 ± 0.021

G18:1/18:2T

25 ± 10

0.135 ± 0.039

S18:1T

21 ± 6

0.074 ± 0.018

SPEG18:1T

20 ± 3

0.095 ± 0.043

PG8/10D

21 ± 4

0.094 ± 0.022

PG10D

20 ± 7

0.056 ± 0.020

PG8M

15 ± 3

0.010 ± 0.004

G8/10MD

15 ± 3

0.009 ± 0.004

: 2% (w/v) of the preconcentrate in DMEM.
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Table 4 SEN formulations for the study of effect of triglyceride in SEN and droplet sizes
of SEN on cytotoxicity (mean ± SD, n =3).
Lipid

Lipid:

Droplet Sizea

Kolliphor®RH40

(nm)

Polydispersity
Index

(Weight Ratio)

a

G18T: G8/10MD (7:3)

1:1

257 ± 112

0.265 ± 0.056

G8T: G8/10MD (1:1)

1:1

30 ± 9

0.068 ± 0.008

G8/10MD

1:1

120 ± 94

0.310 ± 0.063

G8/10MD

1:4

15 ± 3

0.009 ± 0.004

: 2% (w/v) of the preconcentrate in DMEM.
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Table 5 SEN formulations for the study of effect of structure of fatty acid monoester
(FAME) in SEN on cytotoxicity and tight junctions (mean ± SD, n =3).

Fatty Acid Esters (FAE)

Droplet Sizea
(nm)

Polydispersity Index

Fatty acid monoester (FAME), G8T, and Kolliphor®RH40 at 1:1:2 (w/w)

a

PG8M

37 ± 18

0.076 ± 0.031

PG12M

42 ± 16

0.155 ± 0.038

PG16/18M

Phase separated

N/A

PG18M

Phase separated

N/A

G8MD

28 ± 5

0.027 ± 0.015

G8/10MD

29 ± 4

0.031 ± 0.015

G8M

28 ± 4

0.034 ± 0.021

G16/18M

Phase separated

N/A

G18:1M

36 ± 0

0.164 ± 0.040

G18:1/18:2MD

49 ± 22

0.365 ± 0.078

G18:2MD

38 ± 14

0.104 ± 0.035

PEG8/10MD

29 ± 8

0.034 ± 0.011

S12M

26 ± 7

0.038 ± 0.021

S18:1M

34 ± 13

0.099 ± 0.032

SC12M

36 ± 20

0.205 ± 0.043

SPEG12M

26 ± 10

0.184 ± 0.071

SPEG18:1M

27 ± 9

0.121 ± 0.054

: 2% (w/v) of the preconcentrate in DMEM.
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1.2.2 Cell Culture
The MDCK cells were cultured in the T-75 flasks in the culture medium
(cMedium) containing DMEM (with phenol red), 10% FBS, and 1% penicillinstreptomycin solution at 37ºC with 5% CO2/95% air. The cells were split and subcultured
when reached 80% confluence.
1.2.3 Cytotoxicity Study
The MDCK cells were seeded to the 96-well plates at the density of 7000
cells/well in 200 µL cMedium. The cells growing for two days were washed once with
DMEM. Then 200 µL of cMedium, DMEM, 4% Kolliphor®RH40 in DMEM, or SENs of
various concentrations of the preconcentrates were added to each well (n=6) and
incubated at 37oC for two hours. The samples were removed and the cells were washed
once with cMedium. Then, the MTT solution (200 µL, 2.5 mg/mL in cMedium) was
added to each well, and the plates were further incubated for two hours. The MTT
solution was removed and replaced with DMSO (200 µL), and the plates were covered
with foil to protect from the light exposure. The plates were agitated for five min and the
absorbance of formazan in each well was analyzed by a UV spectrophotometer at 560
nm. The cell viability (%) was calculated based on the absorbance and with the cells
treated with cMedium as 100% cell viability.
1.2.4 Effect of SENs on Tight Junctions
The MDCK cells in cMedium at the density of 6.5 x 104 cells/cm2 were seeded on
the Transwell® insert with a surface area of 4.6 cm2/well and membrane pore size of 0.4
µm and incubated at 37oC. The culture media was changed every other day for four days
and then every day for three more days. The TEER value was monitored to measure the
formation of the tight junction. Confluent cell monolayers with the TEER value higher
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than 180 Ω.cm2 were washed with DMEM twice. Then fresh DMEM (2.5 mL) was added
to the receiver chamber, and 1.5 mL of the DMEM, 4% Kolliphor®RH40 in DMEM, or
SENs of various concentrations of the preconcentrates (Table 3-5) were added to the
donor chamber (n=3), and further incubated for two hours. TEER value was measured at
the beginning and every hour during the transport study.
1.2.5 Recovery of Tight Junctions Integrity Pretreated with SENs
The monolayers pre-treated with SENs were washed with cMedium twice and
incubated for twenty-four hours in cMedium. Then, the cMedium in the donor chamber
was removed and replaced with cMedium containing one µL/mL of mannitol, D-[1-14C],
used as the paracellular transport marker. The monolayers were further incubated for two
hours. Samples (0.2 mL) were taken from the receiver chamber for radioactivity assay.
The TEER value was measured at 1, 2, 4, 6, 24, and 26 hours of the recovery period. The
apparent permeability coefficient (Papp) of 14C-mannitol was calculated from the
following equation:
𝑄

𝑃𝑎𝑝𝑝 = 60𝐴𝐶 𝑡 ,
0

where Papp is the apparent permeability coefficient (cm/s), Q is the total
radioactivity permeated throughout the incubation time (DPM, Disintegration per min), A
is the surface area of the Transwell® Insert (4.6 cm2), C0 is the initial radioactivity of the
marker in the donor chamber (DPM/cm3), and t is the total time of the permeation (min).
1.2.6 Quantification of Radioactivity
The samples taken from the recovery study (0.2 mL) were mixed with Ultima
GoldTM scintillation cocktail (3 mL) in a 7-mL scintillation vial. Then, the disintegrations
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per min (DPM) of the radioactive (14C) was counted by a Tri-carb Liquid Scintillation
Analyzer Model B3110 TR (PerkinElmer, CT, USA).
1.2.7 Statistical Analysis
The data are expressed as mean ± standard deviation (n=6 for cell viability, and
n=3 for other studies). The viability was analyzed by one-way ANOVA and the transport
of marker was analyzed by the student’s t-test to compare the difference between the
monolayer pre-treated with SENs and DMEM. The difference was considered significant
when p<0.05.
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1.3 Results and Discussion
1.3.1 Cytotoxicity of Surfactants
The cytotoxicity of FAEs’ micelles was first studied to understand the effect of
the corresponding FAE structure alone. The five FAEs commonly used as surfactants for
SEN were investigated: Kolliphor®RH40, Kolliphor®EL, Kolliphor®HS15, Tween®80
(SPEG18:1M), and Tween®85 (SPEG18:1T). The concentration used was in the range of
0.25-5.00%, higher than the reported CMCs. The reported CMCs of Kolliphor®RH40,
Kolliphor®EL, and Kolliphor®HS15 was 0.039%, 0.010%, and 0.018%, respectively25, 26,
and that of Tween®80 (SPEG18:1M) and Tween®85 (SPEG18:1T) was 0.0014% and
0.0023%, respectively27.
The comparison of the cytotoxicity results was divided into two groups based on
the structural similarity of the FAEs: 1) Kolliphor®RH40, Kolliphor®EL,
Kolliphor®HS15, and 2) Tween®80 (SPEG18:1M) and Tween®85 (SPEG18:1T).
Figure 1A shows the viability of MDCK cells after exposure to Kolliphor®RH40
at the concentration range of 0.25-5.00% (w/v) in DMEM. There was no reduction in
viability after the 2-h exposure, but the viability after 3-h exposure was decreased to
57.38 ± 10.83% and 39.49 ± 3.59% by 4% and 5% of Kolliphor®RH40, respectively.
These results demonstrate that the cytotoxicity caused by Kolliphor®RH40 was both
time- and concentration-dependent. Therefore, the other cytotoxicity studies and transport
studies were limited to two hours to eliminate the cytotoxicity caused by
Kolliphor®RH40.
Kolliphor®EL had a similar effect on the cell viability as Kolliphor®RH40
(Fig.1b): the viability was higher than 90% after the 2-h exposure. This was due to the
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two have a similar structure. Kolliphor®HS15 caused the concentration-dependent
reduction in the cell viability after 2-h exposure (Figure 1B). There are two differences
between Kolliphor®HS15 and Kolliphor®RH40: 1) the numbers of hydroxystearate
chains; and 2) the hydrophilicity of the head group, although both have the similar HLB
value of 15. Kolliphor®HS15 is a mixture of mono- and di-esters of hydroxystearate,
which has less lipid chain compared to Kolliphor®RH40 (three chains). This causes less
intermolecular attraction through the non-polar tails. Further, Kolliphor®HS15 has a
smaller head group (PEG-15) than Kolliphor®RH40 (PEG-40), which further reduces the
intermolecular attraction through the polar heads. Therefore, the monomers of
Kolliphor®HS15 are easier to diffuse out from the micelles than Kolliphor®RH40, which
would have more interaction with the cell membrane to cause higher cytotoxicity. Maher
et al. proposed that it is the monomers which diffuse out from micelles would interact
with the cell membrane to cause cytotoxicity28.
SPEG18:1T did not show any cytotoxicity at the studied concentration range,
whereas SPEG18:1M showed a concentration-dependent reduction in the cell viability
(Fig. 1b). The only difference between SPEG18:1T and SPEG18:1M is the number of
oleate chain (C18:1). The three nonpolar chains in SPEG18:1T caused higher
intermolecular binding as compared to only one chain in SPEG18:1M, which was
correlated to the higher cytotoxicity by Kolliphor®HS15 (one and two chains) as
compared to Kolliphor®RH40 (three chains).
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Figure 1 Cytotoxicity: (A) Kolliphor®RH40 in DMEM at two hours (Solid line), and
three hours (Dashed line) (mean ± SD, n=6); (B) Kolliphor®EL (■, solid line),
Kolliphor®HS15 (■, dashed line), SPEG18:1T (△, solid line), and SPEG18:1M (△,
dashed line) in DMEM after two-hour exposure (mean ± SD, n=6).
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1.3.2 Preparation and Characterization of SENs
The droplet size of SEN containing mono-, di-, or tri-esters of fatty acid with
Kolliphor®RH40 (1:4) was presented in Table 3. These SENs were formulated to study
the effect of the number of fatty acid chains (one, two, and three chains) on the
cytotoxicity of FAEs in SEN. The mean droplet size of these SENs was below 30 nm.
Table 4 presents the composition of the preconcentrates of various SENs and their
droplet size which were formulated to study the effect of triglyceride and droplet size on
the cytotoxicity of G8/10MD in SEN. The mean droplet size of SEN containing
G8/10MD, G18:1T, and Kolliphor®RH40 (7:3:10) was 257 nm, larger than 140 nm,
which should be classified as an emulsion29. The SEN containing G8/10MD, G8T, and
Kolliphor®RH40 (1:1:2) had the mean droplet size of 30 nm. The SEN containing only
G8/10MD and or®RH40 at 1:1 and 1:4, without triglycerides, had the mean droplet size
of 120 and 15 nm, respectively.
Table 5 shows the droplet size of the studied SENs containing FAMEs which
were formulated to study the effect of the structural factors of FAMEs on their
cytotoxicity in SEN and opening of tight junctions. The preconcentrates containing
saturated long-chain FAMEs including PG16/18M, PG18M, and G16/18M caused phase
separation when diluted with DMEM. Therefore, these FAMEs were excluded from
further studies. All other SENs containing FAMEs had the mean droplet size below 50
nm.
1.3.3 Cytotoxicity of SENs
The reduction in the cell viability caused by SENs was found to depend on four
different factors: 1) the numbers of fatty acid chains, 2) the presence of triglycerides, 3)
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the droplet size, and 4) the structures of fatty acid monoester (FAME). Figure 2-4 show
the cell viability after the 2-h exposure to the various SEN formulations.
1.3.3.1 Effect of Numbers of Fatty Acid Chains on the Cytotoxicity of
Fatty Acid Ester in SENs
The above micelle results (Section 1.3.1) show that the compounds exhibiting
high cytotoxicity were either monoester (SPEG18:1M) or the mixture of mono- and diester (Kolliphor®HS15). Therefore, other FAEs (tri-, di-, or monoester of glycerol and
propylene glycol) were studied to further investigate the effect of the number of fatty acid
chains when formulated in SENs. The concentration of SENs used in this study was 4%
(0.8% of tri-, di-, or monoester and 3.2% of Kolliphor®RH40). There was no noticeable
reduction in the cell viability caused by Kolliphor®RH40, the SENs containing FAE with
three chains (G8T, G10T, or G18:1/18:2T), or the SENs containing FAE with two chains
(PG8/10D, or PG10D). However, the SENs containing FAEs with one chain (PG8M or
G8/10MD) decreased the cell viability to 9.05±1.64% and 5.11±0.09%, respectively
(p<0.01). (Figure 2). These results indicate that fatty acid monoester (FAME; one chain)
in lipid droplets is the major component causing cytotoxicity.
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Figure 2 Cytotoxicity of controls (Pattern fill) and SEN containing FAEs (Solid fill).
Black bar: SEN containing fatty acid triesters (three chains); Grey bar: SEN containing
fatty acid diester (two chains); White bar: SEN containing fatty acid monoester (one
chain) (mean ± SD, n=6). *Significantly lower than DMEM (p<0.01).
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1.3.3.2 Effect of Triglyceride on the Cytotoxicity of Fatty Acid
Monoester in SEN
This study aims to investigate whether the presence of triglyceride would alter the
cytotoxicity of fatty acid monoester (FAMEs) in SEN. From Section 1.3.3.1, the viability
was found to decrease with the presence of FAMEs (PG8M or G8/10MD). Therefore,
G8/10MD was selected to formulate SENs with and without triglyceride. Two
triglycerides were used including G18:1T or G8T, and Kolliphor®RH40 was used as the
surfactant. Four SEN formulations were formulated (Table 4). The first two SENs were
SENs containing triglycerides (G18:1T or G8T), and the other two SENs were SENs
without triglycerides. These four SENs were diluted at various dilutions to prepare SENs
which contain the same concentration of G8/10MD.
Figure 3 demonstrates the relationship between the concentration of G8/10MD in
each SEN and the cell viability after 2-h exposure to the corresponding SENs. At the
concentration of G8/10MD from 0.05% - 0.25%, the cell viability reduced by SENs
without triglycerides significantly (p<0.05) lower than the viability reduced by SENs
containing triglycerides. For example, at 0.05% of G8/10MD, SENs without triglycerides
reduced the cell viability to 50-60%, whereas SENs containing triglycerides resulted in
the cell viability higher than 100%. Similarly, when the concentration of G8/10MD in
SENs was 0.15%, SENs without triglycerides decreased the viability to below 10%,
whereas SENs containing triglycerides resulted in the viability of 80-100%.
These results show that the presence of C8 and C18:1 triglycerides (G8T and G18:1T,
respectively) in the SEN formulation can reduce the toxicity of FAME (G8/10MD). And
this may be because the addition of triglycerides in the SENs increases the intermolecular
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interaction in the lipid droplets which may help to retain G8/10MD monomers within the
droplets resulted in less G8/10MD monomer to interact with the cell membrane.
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Figure 3 Cytotoxicity of G8/10MD in SENs containing triglycerides either G18:T or
G8T (Solid fill) and SENs without triglyceride (Pattern fill) (mean ± SD, n=6). *:
Significantly lower than SEN containing triglycerides (p<0.05).
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1.3.3.3 Effect of Droplet Size of SEN on the Cytotoxicity of Fatty Acid
Monoester in SEN
In addition to the effect of triglyceride, the effect of the droplet size of SEN was
also investigated whether the difference in SEN’s droplet size would alter the cytotoxicity
of fatty acid monoester (FAMEs) in SEN. Four SENs containing G8/10MD described in
Table 4 were also used in this study.
The SEN containing triglycerides were formulated to have different droplet sizes.
SEN containing G8/10MD, G18:1T, Kolliphor®RH40 (3:7:10) had the droplet size of 260
nm, whereas the droplet size of SEN containing G8/10MD, G8T, Kolliphor®RH40
(1:1:2) was 30 nm. Figure 4A demonstrates the comparison between 260-nm and 30-nm
SEN containing triglycerides. At 0.25% and 0.3% G8/10MD, the cell viability reduced by
30-nm SEN was significantly (p<0.05) lower than 260-nm SEN (47.89 ± 5.13% vs
137.78 ± 40.24% and 8.44 ± 0.46% vs 72.24 ± 17.25%, respectively).
The SEN without triglycerides were also formulated to have different droplet
sizes. The SEN containing G8/10MD and Kolliphor®RH40 (1:1) had the droplet size of
120 nm, while SEN containing G8/10MD and Kolliphor®RH40 (1:4) had the droplet size
of 15 nm. Figure 4B shows the comparison between 120-nm and 15-nm SEN without
triglycerides. At 0.075% of G8/10MD, the cell viability reduced by 15-nm SEN was
significantly (p<0.05) lower than 120-nm SEN (16.26 ± 5.23% vs 48.48 ± 14.12%).
It can be concluded that the toxicity of G8/10MD in lipid droplets was higher with
the smaller droplet sizes. This may be due to 1) smaller lipid droplets have a larger
surface area than bigger lipid droplets at the same concentration, leading to more contact
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between the cells and G8/10MD; and 2) the diffusion of G8/10MD is easier from smaller
droplets than from bigger droplets.
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Figure 4 Cytotoxicity of G8/10MD in SEN with the same compositions but difference in
droplet size. (A): the comparison between 260-nm and 30-nm SEN containing G8/10MD
with triglycerides and Kolliphor®RH40; (B): the comparison between 120-nm and 15-nm
SEN containing G8/10MD and Kolliphor®RH40 (mean ± SD, n=6). *: Significantly
lower than 260-nm SEN (p<0.05), **: Significantly lower than 120-nm SEN (p<0.05).
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1.3.3.4 Effect of Structures of Fatty Acid Monoester on their
Cytotoxicity in SEN
SENs containing various FAMEs were further formulated (G8T: FAME:
Kolliphor®RH40 =1:1:2) to examine the other factors of FAMEs such as chain length,
hydrophilic head group, and number of the double bond in the chain. As a result of
section 1.3.3.2 and 1.3.3.3, the addition of G8T in SEN was performed to minimize the
toxicity of FAMEs and the droplet size of all SEN containing FAMEs was formulated to
be below 50 nm in order to avoid any complication caused by the difference in size.
Figure 5 shows the cytotoxicity of the cell monolayer exposed to SENs containing
various FAMEs. The SENs containing medium-chain FAME of glycerol and propylene
glycol (HLB 4-7) resulted in <10% cell viability, while the SENs containing mediumchain FAME of sorbitan, PEG-8, sucrose, and PEGylated sorbitan (HLB>8) resulted in
cell viability of 80-129%. The structural difference between the two groups of FAMEs is
the latter has a bigger hydrophilic head group. These results indicate that the increase in
hydrophilicity of the head groups equal or greater than sorbitan can reduce the
cytotoxicity of FAME, which may be due to 1) the stronger interaction between the larger
head group helps to maintain the monomer within the droplets, and 2) the more
hydrophilic monomers in the medium trend to self-assembling rather than perturbating to
the cell lipophilic membrane.
The SENs containing the long-chain FAMEs with a single double bond (G18:1M,
S18:1M, and SPEG18:1M) resulted in no noticeable cytotoxicity, while the SENs
containing the long-chain FAMEs with two double bonds (G18:1/18:2MD and
G18:2MD) reduced the cell viability to 46% and 18%, respectively. These results indicate
that the higher numbers of double bonds cause higher cytotoxicity of FAMEs.
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Figure 5 Cytotoxicity of fourteen fatty acid monoesters (FAMEs) in SEN. Grey bar:
medium-chain FAMEs; White bar: Long-chain FAMs. (mean ± SD, n=6).
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1.3.4 Effect of SENs on Tight Junction
1.3.4.1 TEER Reduction
Transepithelial electrical resistance (TEER) measurement has been widely used to
assess the integrity of tight junctions. The reduction in TEER value is an indicator of
compromised tight junctions altering the paracellular permeability of epithelium. Figure 6
shows the change in TEER value of the monolayer pretreated with SENs for two hours.
The TEER of the monolayers pretreated with the SENs containing only G8T and
Kolliphor®RH40 (1:4), or PG10D and Kolliphor®RH40 (1:4) at 4% (w/v) was constant
after two hours indicating the intact tight junction integrity. The TEER reduced by the
SENs containing PEG8/10MD, S12M, SC12M, and SPEG12M was only 76-89%.
However, the presence of medium-chain FAME of glycerol or propylene glycol reduced
the TEER to approximately 30%. These results demonstrate that the medium-chain
FAME of glycerol or propylene glycol (HLB 4-7) had a higher effect on tight junction
opening than the medium-chain FAME of PEG-8, Sorbitan, Sucrose, and PEGylated
sorbitan (HLB>8), which was correlated to their cytotoxicity effects.
The SENs containing the long-chain FAMEs with a single double bond (G18:1M,
S18:1M, and SPEG18:1M) resulted in no reduction in TEER, while the SENs containing
the long-chain FAMEs with two double bonds (G18:1/18:2MD and G18:2MD) reduced
the TEER to 61% and 72%, respectively. This indicates that long-chain FAMEs with two
double bonds have a higher effect on tight junction opening than the other long-chain
FAMEs. And similar to medium-chain FAMEs, there was a correlation between the
TEER reduction and cell viability.
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1.3.4.2 Mechanism of Action
Maher et al. stated that when FAE formed micelles, the FAE monomers diffusing
out from its micelles to interact with the cell phospholipid bilayers, which consequently
alters the cell membrane integrity5, 28. Therefore, intermolecular attraction force between
the FAEs, and FAE with other excipients, plays a key role in determining the diffusion of
the FAE monomers out of the lipid droplets to interact with the epithelial layer.
One of the parameters indicating the intermolecular binding force of FAME
molecules is the melting point. The melting point of G18M, G18:1M, G18:1/18:2MD,
and G18:2MD is 54-64˚C, 24˚C, 14-19˚C, and < 0 ˚C, respectively30. The presence of
double bond decreases the melting point which is corresponding to the decrease in
intermolecular attraction29, 31. The strong intermolecular attraction of the saturated longchain FAMEs makes these molecules binding together and unable to be dispersed by the
emulsifier to form nanodroplets. FAME molecules with double bond have less
intermolecular attraction and are easier to be mixed and incorporated into the droplets
with the emulsifier. Further, because of the lower intermolecular attraction, the
monomers with double bond are easier to escape from the droplets and to interact with
the tight junctions to enhance the permeability. The more double bonds, the bigger such
effects.
The melting point of G8MD, G10MD, G12M, G18M (all with saturated chain) is
30-34˚C, 40-41˚C, 56-60˚C, 54-64˚C, respectively, indicating that the longer the chain
length the higher the intermolecular attraction30. Due to this reason, FAME monomers
with shorter chain-length can diffuse easier out of the lipid droplets and cause higher
cytotoxicity and permeation enhancement.
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However, the interactions of the FAMEs with the cellular membrane not only
depend on their chain length but also depend on the structure of the chain (saturated vs
unsaturated). The medium-chain FAMEs (G8M, G8MD, and G8/10MD) had higher
cytotoxicity and effect on tight junctions than the long-chain FAMEs with double bond(s)
(G18:1M, G18:1/18:2MD, and G18:2MD), even though the formers have a higher
melting point (higher intermolecular attraction) than the latter. Because the presence of
double bond kinks in the hydrocarbon tail32, this may make the monomers difficult to
interact with tight junctions. As a result, the presence of double bonds in the long-chain
FAME increases the monomer diffusion out of the lipid droplets, but reduces the
monomer interaction with tight junctions.
In conclusion, both intermolecular attraction and structure of FAMEs influence
their cytotoxicity and effect on the tight junction. The intermolecular attraction among
FAMEs in the lipid droplets determines how easy the FAME to diffuse out of the
droplets, while the structure of the FAME determines its interaction with the tight
junctions. FAMEs with less intermolecular attraction than di- and tri-esters had more
cytotoxic and higher interaction with tight junctions. Among the FAMEs, the degree of
these effects are in the following order: medium-chain with small hydrophilic head (PG
and G) > long-chain with two double bonds > medium-chain with large head (S, PEG,
SC, and SPEG) ≈ long-chain with single double bond > saturated long-chain, which are
consistent with the intermolecular attraction force (low-high) of the various FAEs. And
the more kinks in the monomer’s tail caused by the double bond, the less the monomer to
perturbate into the cell membrane, resulting in less cytotoxicity and opening of tight
junction.
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Figure 6 Change in TEER of the MDCK monolayer after the 2-h exposure to SEN
containing fourteen FAMEs (Solid fill) and after 24-h recovery (Pattern fill). Black bar:
controls; Grey bar: medium-chain FAMEs; White bar: Long-chain FAMs. (mean ± SD,
n=3).
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1.3.5 Recovery of Tight Junctions Integrity Pretreated with SENs
14

C-Mannitol is a commonly used paracellular transport marker because it usually

permeates passively through the paracellular route 33. Figure 6 and 7 present the TEER
value and the Papp of 14C-mannitol across the monolayer recovered for twenty-four hours
after the 2-h exposure to SENs containing FAMEs, respectively. The Papp of 14C-mannitol
across the monolayer pre-treated with the SENs containing PG8M, PG12M, G8MD,
G8/10MD, G8M was about 10 times higher than the control (p<0.05), and the TEER of
these monolayers remained as only about 30% after the 24-h recovery period. The
increase in mannitol permeability confirmed the effect of SEN containing FAME on
paracellular permeability. The Papp of 14C-mannitol across the monolayer pre-treated with
the SENs containing PEG8/10MD and SC12M were also increased for 2.4 and 1.8-fold,
while SENs containing S12M and SPEG12M had similar mannitol transport, as
compared to the control.
The recovery of the monolayers pretreated with the SEN containing mediumchain FAMEs of small heads (glycerol or propylene glycol) was much less than the
monolayers pretreated with the SENs containing medium-chain FAMEs of larger heads
(PEG-8, Sorbitan, Sucrose, and PEGylated sorbitan). This result together with the results
of cytotoxicity confirms that the large head group of the FAME increases the
intermolecular attraction between the heads and thus restrains the diffusion of the FAME
monomers out of the droplets to interact with the cell monolayer.
There was no significant (p>0.05) difference in the Papp of 14C-mannitol through
the monolayers pre-treated by S18:1M and SPEG18:1M compared to the control. But the
monolayer pre-treated with G18:1M, G18:1/18:2MD, and G18:2MD exhibited a
significant (p<0.05) increase in the transport of 14C-mannitol for 1.7, 1.8, and 3.6 folds as
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compared to the control, respectively. These results demonstrate that the long-chain
FAMEs with smaller hydrophilic heads and more double bonds had more effect on
opening the tight junction.
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Figure 7 Transport of 14C-Mannitol through the MDCK cell monolayer recovered for
twenty-four hours after the 2-h exposure to SEN containing FAMEs. Black bar: controls;
Grey bar: medium-chain FAMEs; White bar: Long-chain FAMs (mean ± SD, n=3). *:
Significant increase compared to the monolayer pre-treated with DMEM (p<0.05).
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1.4 Trends and Limitations
Literature reviews show that medium-chain fatty acids (MCFA) exhibit a
capability to modulate the localization or conformation of occludin and ZO-1 which are
the essential protein components of tight junctions 34. The modulation of these adhesion
proteins results in the reduction in TEER and selectively alters the paracellular
permeability of the epithelial membrane. MCFA is also reported to inhibit phospholipase
C-dependent pathway35. Ward et al. demonstrated that the inhibition of phospholipase Cbeta in MDCK cell monolayer can lead to an increase in paracellular permeability by the
disorganization of actin filaments36. The interaction between occludin protein and longchain fatty acids (LCFA) was also observed by Jiang et al. resulted in the reduction in
TEER37, 38. Oleic acid (C18:1) did not modulate the tight junction proteins, but it was
found to increase protein kinase C and disperse into lipid bilayer which also induced the
paracellular permeability37, 39, 40.
The TEER results in this study show that fatty acid monoester (FAME) in SEN
can also interact with the tight junctions. However, there has been limited investigation of
the effect of fatty acid ester (FAE) on tight junctions, especially FAME. To the best
knowledge of the authors, only Labrasol (PEG8/10MD) and sucrose laurate (SC12M)
which are FAME reported to exhibit to capability to open the tight junctions through the
localization or conformation of occludin and ZO-1 proteins41, 42.
The TEER reduction found with medium-chain FAMEs and long-chain FAMEs
with two double bonds was correlated to the effect of MCFA and LCFA reported in the
previously mentioned literature. It can be inferred that SEN containing FAME can
enhance paracellular permeability by compromising the tight junctions through the
similar mechanisms to fatty acids.
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1.5 Conclusion
Among the FAEs (mono-, di-, and triesters), the fatty acid monoester (FAME) is
the main excipient causing concentration-dependent cytotoxicity and opening of tight
junction. When FAME was formulated in SEN, the cytotoxic of FAME is reduced with
the presence of triglycerides, the increase in droplet size, and the higher intermolecular
interaction within lipid droplets.
Therefore, four FAMEs (G8/10MD, G18:1M, G18:2MD, and PEG8/10MD)
which exhibit capability to open tight junctions and consist of various structural factors
were selected to formulate SENs with triglyceride and evaluated for its efficacy and
safety in delivering insulin through i.n. route in the next Chapter.
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CHAPTER 2
IN VITRO EVALUATION OF SEN CONTAINING FATTY ACID MONOESTERS
FOR NASAL DELIVERY OF INSULIN
From Chapter 1, SEN containing FAMEs could open the tight junctions of the cell
monolayer. Therefore, in this present study, SENs containing FAMEs were further
evaluated for their capability to enhance insulin across the opened tight junctions, in
vitro. One of the concerns, when insulin is in the aqueous phase of SEN, is that insulin
being a natively structured amyloidogenic protein can aggregate and form fibril or
filament. The formation of fibrils reduces insulin bioactivity. Nielssen et al. explained
that nucleation and fibril growth of insulin molecule can be controlled by hydrophobic
and electrostatic interactions. Also, some of the excipients e.g. sucrose, Trimethylamine
N-oxide (TMAO), quinone, etc. have been reported for their ability to stabilize and
prevent insulin aggregation 43-45. Therefore, SEN which contains surfactant and cosurfactant may also prevent the fibril formation of insulin.
The human airway epithelial cells (Calu-3), an adenocarcinoma cell line derived
from Caucasian males, can form a monolayer with a mucus layer and functional tight
junctions, desmosomes, and zonular adherence 46, 47. Both MDCK and Calu-3 have an
ability to form monolayer with tight junctions and are a good model for paracellular
transport47. However, only Calu-3 exhibits the mucus layer which can better mimic the
nasal epithelium than MDCK. The mucus layer secreting by Calu-3 consists of mucin
genes 5 (MUC5) and MUC5B which are the major mucins present in human healthy
airway secretions and chronic disease conditions, respectively46, 48, 49. In addition,
Furubayashi et al. reported that the paracellular permeability of MDCK could be
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underestimated for the nasal delivery model due to the excessive tight cellular
junctions50. Therefore, Calu-3 cell line has been widely used as a cell culture model for
nasal drug absorption and was selected for the current study to optimize the SEN
formulation for nasal delivery of insulin 51-53.
The objective of this study was 1) to evaluate the cytotoxic and permeationenhancing effects of SENs for the nasal delivery of insulin on Calu-3 cells and 2) to
investigate the stability of the insulin in the selected SEN formulation by Thioflavin T
assay for the determination of fibril formation.
2.1 Materials
Acetic acid (Glacial) and Kolliphor®RH40 was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Acetonitrile ≥ 99.8% for HPLC, Eagle's Minimum Essential
Medium (EMEM), Trifluoroacetic acid (TFA) were purchased from VWR (West Chester,
PA, USA). Captex®8000 (G8T, C8 Triglycerides) and Capmul® MCM (G8/10MD, C8/10
Mono- and Di-glycerides) were kindly gifted by Abitec Corporation (Janesville, WI,
USA). Dimethyl sulfoxide (DMSO) and Methanol (≥99.8%) were purchased from VWR
(West Chester, PA, USA), and 3-(4.5-dimethylthiazol-2-yl)-2.5diphenyltetrazoliumbromide (MTT), Hydrochloric acid (1M), and Thioflavin T (ThT)
were purchased from Thermofisher Acros Organics (Morris Plains, NJ, USA).
Dulbecco’s Phosphate-Buffer Saline (DPBS), pH 7.0 without calcium/magnesium, and
penicillin-streptomycin solution were purchased from Hyclone (Logan, UT, USA). Fetal
Bovine Serum (FBS) was purchased from Atlanta Biologicals (Flowery Branch, GA,
USA). Human insulin and FITC-Insulin (Human) were purchased from Sigma-Aldrich,
Co. (St. Louis, MO, USA). Human lung cancer cell line (Calu-3) was purchased from
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ATCC® (Rockville, MD, USA). PECEOL™, Maisine®CC, and Labrasol®ALF were kindly

gifted from Gattefossé (Paramus, NJ, USA). Trypsin (0.25%) with 0.53 mM
ethylenediaminetetra acetic acid (EDTA) was purchased from Mediatech Inc. (Manassas,
VA, USA).
2.2 Methods
2.2.1 Preparation and Characterization of SENs Containing FAME
Four FAMEs were used in this experiment including G8/10MD, G18:1M,
G18:2MD, and PEG8/10MD. The preconcentrate of SEN was prepared by mixing G8T,
FAME, and Kolliphor®RH40 at 1:1:2 weight ratio and shaken in a MaxQ™ 4000
Benchtop Orbital Shaker (Thermo Scientific™, USA) for three hours (300 rpm, 37 °C).
Then, the preconcentrate was diluted with PBS to form SEN-G8/10MD, SEN-G18:1M,
SEN-G18:2MD and SEN-PEG8/10MD at 0.4-4% (w/v) for cytotoxicity study and 0.8%
for transport study. The droplet sizes and zeta potential of SENs were measured by a
Zetasizer®Nano ZS (Malvern Instrument Inc., USA). The FITC-insulin (1 IU/mL) was
added to the SENs used in the transport study.
2.2.2 Cell Culture
The Calu-3 cells were cultured in the T-25 flasks in the culture medium
(cMedium) containing EMEM (with phenol red), 10% FBS, and 1% penicillinstreptomycin solution at 37ºC with 5% CO2/95% air. The cells were split by trypsin
(0.25%) with 0.53 mM EDTA solution and subcultured when reached 90% confluence.
2.2.3 Cytotoxicity Study
The Calu-3 cells were seeded to the 96-well plates at the density of 40,000
cells/well in cMedium (200 µL). The cells were grown for 22-24 hours before the
45

experiment. The cMedium was removed and 200 µL of fresh cMedium, DPBS, or SENs
(0.4-4% of the preconcentrates in DPBS) were added to each well (n=6) and incubated at
37oC for two hours. The test formulations were removed, and the cells were washed once
with cMedium. Then, the MTT solution (200 µL, 2.5 mg/mL in cMedium) was added to
each well, and the plates were further incubated for two hours. The MTT solution was
removed and replaced with DMSO (200 µL), and the plates were covered with foil to
protect from the light exposure. The plates were agitated for five min and the absorbance
of formazan at 560 nm in each well was analyzed by a spectrophotometer Glomax®
Discover microplate reader (Promega, USA). The cell viability (%) was calculated based
on the absorbance and with the cells treated with cMedium as 100% cell viability. The
half-maximal inhibitory concentration (IC50) was calculated for each SEN by GraphPad
Prism 8.
2.2.4 In Vitro Permeation of FITC-insulin in SEN
The Calu-3 cells in cMedium at the density of 5 x 105 cells/cm2 were seeded on
the Transwell® insert with a surface area of 0.33 cm2/well and membrane pore size of 0.4
µm and incubated at 37oC. The culture media was changed every other day. The Calu-3
monolayer was typically formed on the Transwell® insert after 13-15 days. The TEER
value was monitored to measure the formation of tight junctions. The monolayers with
TEER value higher than 500 Ω.cm2 were used in the further experiment 54, 55. The
confluent monolayers were washed with DPBS once. Then fresh DPBS (1 mL) was
added to the receiver chamber, and 0.3 mL of the SENs containing FITC-insulin (1
IU/mL) were added to the donor chamber (n=3), and further incubated for two hours.
Samples (0.2 mL) were taken at 30, 60, 90, and 120 min from the receiver chamber and
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replaced with fresh DPBS. The TEER value was measured at the beginning and every
hour during the transport study.
The fluorescence intensity of FITC-insulin was analyzed by Glomax® Discover
microplate reader at excitation/emission wavelength of 475/550-550 nm. The SENs
containing FITC-insulin added to the donor chamber was diluted 5 times with methanol
before analyzing for fluorescence and was used as the initial fluorescence. The samples
from the receiver chamber were analyzed for fluorescence and were used to calculate the
cumulative transport of FITC-insulin. The cumulative transport of FITC-insulin was
presented as the percentage of the initial fluorescence.
2.2.5 Recovery of Monolayer Integrity Pretreated with SENs
After the 2-h transport study, the monolayers were washed with cMedium twice
and incubated for 24 hours in cMedium. The TEER value was measured at 1, 2, 4, 6, 12,
and 24 hours of the recovery period.
2.2.6 Thioflavin T Assay
SEN-G8/10MD was used in this study. The SEN-G8/10MD was prepared by
diluting the preconcentrate with insulin solution in 0.01M HCl (pH 2) or DPBS (pH 7.4)
to form 1SEN-G8/10MD and 5SEN-G8/10MD (1% and 5% of preconcentrates,
respectively) containing 2 mg/mL of insulin. The insulin solution in 0.01M HCl was used
as a positive control for fibril formation. Blank diluent, blank 1SEN-G8/10MD, and
blank 5SEN-G8/10MD in both 0.01M HCl and DPBS were used as a background
reading. Table 6 summarizes the tested formulations used in the study.
Thioflavin (ThT) was dissolved in DPBS and prepared as 1 mM stock solution.
The stock solution (0.1 mL) was added to each formulation (10 mL, n=3) and incubated
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at 60˚C to accelerate the fibril formation of insulin. The sample (20 µL) was taken at 0, 3,
5, 12, and 24 hours into 96-well plate. The ThT fluorescence was measured immediately
after the samples were withdrawn by using the SpectraMax microplate reader (Molecular
Devices, USA) at excitation/emission wavelength of 482/450 nm and 37°C.
2.2.7 Statistical Analysis
The data are expressed as mean ± standard deviation (n=6 for cell viability, and
n=3 for transport study and ThT assay). The viability and transport of FITC-insulin were
analyzed by one-way ANOVA followed by Tukey’s HSD Post-hoc test. The fluorescence
intensity in ThT assay was analyzed by paired t-test to compare the difference between
the fluorescence at the studied time with the corresponding initial fluorescence at time
zero. The difference was considered significant when p<0.05.
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Table 6 Details of formulations analyzed by Thioflavin T assay.
Sample# Formulation

Diluent

1

Blank diluent

0.01M HCl (pH 2)

2

Blank 1SEN-G8/10MD

0.01M HCl (pH 2)

3

Blank 5SEN-G8/10MD

0.01M HCl (pH 2)

4

Insulin solutiona

0.01M HCl (pH 2)

(positive control)

a

5

Insulin in 1SEN-G8/10MD

0.01M HCl (pH 2)

6

Insulin in 5SEN-G8/10MD

0.01M HCl (pH 2)

7

Blank diluent

DPBS (pH 7.4)

8

Blank 1SEN-G8/10MD

DPBS (pH 7.4)

9

Blank 5SEN-G8/10MD

DPBS (pH 7.4)

10

Insulin solution

DPBS (pH 7.4)

11

Insulin in 1SEN-G8/10MD

DPBS (pH 7.4)

12

Insulin in 5SEN-G8/10MD

DPBS (pH 7.4)

: 2 mg/mL of human insulin was used in all formulations containing insulin.
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2.3 Results and Discussion
2.3.1 Preparation and Characterization of SENs Containing Selected FAMEs
The mean droplet sizes of the 0.8% SENs including SEN-G8/10MD, SENG18:1M, SEN-G18:2MD and SEN-PEG8/10MD were 29±4, 36±7, 38±14, 29±8 nm,
respectively. The mean droplet size of all the SENs was approximately 30-40 nm and
remained unchanged from 0.4-4%. The zeta potential of the SEN-G8/10MD, SENG18:1M, SEN-G18:2MD and SEN-PEG8/10MD were -4.49±1.14, -2.35±0.74, 1.32±0.67, and -3.92±0.20 mV, respectively. This indicates that the difference in FAME
types did not significantly (p>0.05) affect the zeta potential of the SENs.
2.3.2 Cytotoxicity of SEN Containing Selected FAMEs
Figure 8 shows that the reduction in the viability of the cells exposed to SENG8/10MD, SEN-G18:2MD and SEN-PEG8/10MD was concentration-dependent.
However, no reduction in the cell viability was observed by SEN-G18:1M. The cell
viability exposed to all the SENs at 0.8% (containing 0.2% of FAMEs) was higher than
80% indicating non-toxic at this concentration. Therefore, the SENs at 0.8% were
selected for further transport study. Table 7 shows the calculated IC50 of the SENs. The
highest IC50 was found with SEN-G18:1M which was higher than SEN-PEG8/10MD,
SEN-G18:2MD, and SEN-G8/10MD, respectively. These results were correlated to the
cytotoxicity results in MDCK cells as reported in Chapter 1.
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Figure 8 Cytotoxicity of (♦) SEN-G8/10MD; (■) SEN-G18:1M; (▲) SEN-G18:2MD;
(✕) SEN-PEG8/10MD at various concentrations (mean ± SD, n=6).

Table 7 The half maximal inhibitory concentration (IC50) of SENs containing the
selected FAMEs.
SENs

IC50 (% v/v)

SEN-G8/10MD

0.2367 ± 0.0076

SEN-G18:2MD

0.2805 ±0.0177

SEN-PEG8/10MD

0.5586 ± 0.0194

SEN-G18:1M

>1
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2.3.3 In Vitro Permeation of FITC-insulin in SEN
The cumulative transports of FITC-insulin achieved by PBS, Kolliphor®RH40
(1%), and SENs (0.8%) were shown in Figure 9. After 2-h transport study, the cumulative
transport of FITC-insulin achieved by PBS, Kolliphor®RH40 (1%), and SEN-G18:1M
were similar (0.05±0.01%, 0.17±0.10% and 0.21±0.18, respectively). However, the SENG8/10MD, SEN-G18:2MD, and SEN-PEG8/10MD significantly (p<0.05) increased the
transport of FITC-insulin to 3.03±0.80%, 0.68±0.27%, 0.61±0.39%, respectively. The
increasing orders of insulin transport were consistent with the IC50 of FAMEs (low –
high). The transport of insulin at 30 min achieved by SEN-G8/10MD and SENPEG8/10MD was significantly (p<0.05) higher than PBS, Kolliphor®RH40, and the other
SENs indicating that the permeation-enhancing effect of these two occurred rapidly. The
transport of insulin achieved by SEN-G8/10MD was also significantly (p<0.05) higher
than SEN-PEG8/10MD at any time point showing that SEN-G8/10MD had the highest
capability as a permeation enhancer of insulin across the cell monolayer.
2.3.4 Recovery of Monolayer Integrity Pretreated with SENs
Figure 10 shows the TEER value of the cell monolayers during the 2-h transport
study and 24-h recovery. After 2-h transport study, the TEER was reduced by SENG8/10MD, SEN-G18:2MD, and SEN-G18:1M for about 50%, 40%, and 30%,
respectively, indicating the compromised tight junctions. The reduction in TEER during
the transport study was correlated to the increase in the transport of insulin by all the
SENs, except SEN-PEG8/10MD. The TEER was slightly increased by SENPEG8/10MD for about 12%, which may be because PEG8/10MD may involve in cell
proliferation. The MTT assay (Figure 8) shows that the viability of the cells exposed
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PEG8/10MD at the concentration ≤ 0.2% was also increased to about 120-130%,
indicating the increase in mitochondria function which is essential for the cell
proliferation. The change in TEER value caused by all the SENs reversed to higher than
90% within 12 hours and fully recovered after 24 hours. The recovery in TEER reduction
indicates the reversible opening of tight junction by the SEN at the studied concentration
(0.8%).

53

Cumulative transport of FITC-insulin (%)

4.5

*, **

4.0
3.5
3.0
2.5
2.0
1.5

*, **

1.0

*

0.5

*
0.0
0

30

60

90

120

150

Time (min)

Figure 9 Cumulative transport of FITC-insulin across Calu-3 cell monolayer achieved
by: (♦) PBS; (■) 1% Kolliphor®RH40; (✕) 0.8% SEN-G8/10MD; (●) 0.8% SENG18:1M; (△) 0.8% SEN-G18:2MD; and (○) 0.8% SEN-PEG8/10MD (mean ± SD, n=3).
*: Significantly higher than PBS (p<0.05); **: Significantly higher than all other groups.
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Figure 10 TEER value of the Calu-3 monolayer during and after the 2-h exposure to (♦)
PBS; (■) 1% Kolliphor®RH40; (✕) 0.8% SEN-G8/10MD; (●) 0.8% SEN-G18:1M; (△)
0.8% SEN-G18:2MD; and (○) 0.8% SEN-PEG8/10MD (mean ± SD, n=3).
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2.3.5 Determination of Insulin Stability in Aqueous Phase of SEN by ThT
Assay
ThT is a fluorescence dye which can bind to the amyloid fibrils of proteins or
peptides. Upon binding between ThT and fibrils, ThT increases the fluorescence intensity
at 482/450 nm emission/excitation wavelength. Therefore, ThT has been widely used to
monitor the fibril formation of various proteins including insulin. Two pH conditions
have been used in the current study including pH 2 and pH 7.4. Insulin solution at pH 2
usually stays as monomer or dimer which increases the rate of fibril formation, while
insulin at pH 7.4 favors to form tetramer or hexamer 43. The insulin solution (2 mg/mL,
pH 2) and the incubation temperature at 60˚C have been proved to be the accelerated
conditions for insulin to form fibrils 44, 56. Therefore, insulin solution at pH 2 was used as
a positive control and the formulations were incubated at 60˚C to accelerate the fibril
formation.
Figure 11 shows the ThT fluorescence of various test formulations subtracted
from their corresponding background reading including blank diluent, blank 1SENG8/10MD and blank 5SEN-G8/10MD. The significant (p<0.05) increase in fluorescence
intensity at 12-h and 24-h incubation at 60˚C was observed with insulin solution (pH 2)
and insulin in 1SEN-G8/10MD (pH 2) as compared to their initial fluorescence, while
insulin in 5SEN-G8/10MD (pH 2) showed the similar fluorescence from initial to 24
hours. When insulin was in the solution or aqueous phase of SEN-G8/10MD at pH 7.4,
there was no change in fluorescence intensity indicating that there was no fibril formation
within 24 hours. The result was expected since the insulin at pH 7.4 has been reported to
exist as dimer or tetramer which are less susceptible to fibril formation. By using the
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accelerated conditions, the results indicated that SEN-G8/10MD could prevent the fibril
formation of insulin and the prevention is concentration-dependent.
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Figure 11 ThT fluorescence intensity-time profile under accelerated condition indicating
the fibril formation of insulin (2 mg/mL) in various formulations including (♦) insulin
solution (pH 2); (■) insulin in 1SEN-G8/10MD (pH 2); (△) insulin in 5SEN-G8/10MD
(pH 2); (✕) insulin solution (pH 7.4); (●) insulin in 1SEN-G8/10MD (pH 7.4); and (○)
insulin in 5SEN-G8/10MD (pH 7.4); (mean ± SD, n=3). *: Significantly higher their
corresponding initial fluorescence at time zero (p<0.05).

58

2.3 Trends and Limitations
As mentioned earlier, SEN has been initially developed to enhance the delivery of
lipophilic drugs by increasing the solubility of the drug in SEN droplets. The soluble
form of drug molecules can easily absorb via the transcellular route. Since 2008, our
laboratory has developed the complex formation technique to increase lipophilicity of
hydrophilic drugs e.g. beta-lactamase, calcitonin, insulin, etc. Then, the hydrophilic drug
complex can be loaded into the SEN droplets resulted in the significant increase in the
relative bioavailability of these hydrophilic drugs, in vivo. Until now, there are many
research papers applied the similar procedure to load hydrophilic drugs in the SEN
droplets and have been successfully enhanced the bioavailability of hydrophilic drugs
through many routes of administration57-59.
However, the coadministration of hydrophilic drug in the aqueous phase of SEN
remains limited, especially for intranasal delivery. Sintov et al., coadministered insulin in
the aqueous phase of the SEN which was formulated without FAME. It was found that
the relative bioavailability was less than 1% when administered intranasally. In this
Chapter, when SEN formulation lacks FAMEs, SEN loses its capability to enhance the
transport of insulin. This confirms that the permeation enhancement of SEN depends on
the proper selection of excipients and the main excipient in SEN exhibiting the tight
junction opening is FAME.
The limitation in this Chapter is that the concentration of SEN containing FAME
which was optimized on Calu-3 monolayer for both cytotoxicity and permeation
enhancement cannot be applied directly toward in vivo concentration. The monolayer
culture has limitations to reflect the actual nasal epithelium which consists of multiple
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layers, different morphology, mucociliary clearance, cilia and hairs, etc. Therefore, ex
vivo evaluation was performed to select the safe and efficient concentration of SEN for in
vivo study.
2.4 Conclusion
SEN-G8/10MD, SEN-G18:2MD, and SEN-PEG8/10MD can significantly
(p<0.05) enhance the transport of insulin across the Calu-3 monolayer. The SENG8/10MD at non-toxic concentration showed the highest permeation-enhancing effect on
insulin as compared to the other FAMEs. The SEN-G8/10MD enhance the transport of
insulin by compromising the tight junctions, but the tight junction integrity was recovered
after 12 hours. The co-administration of insulin with SEN-G8/10MD can prevent the
fibril formation of insulin, and the prevention was concentration-dependent. Therefore,
SEN containing G8/10MD (SEN-G8/10MD) was selected for further studies in the next
Chapter.
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CHAPTER 3
EX VIVO PERMEATION AND TOXICITY OF INSULIN IN SEN CONTAINING
G8/10MD
A literature review shows that G8/10MD has been studied for the nasal delivery
of some drugs. The highest concentrations of G8/10MD reportedly used in nanoemulsion
were 15% for the in vivo study in rats and 20% for the ex vivo study on the excised nasal
mucosa from either goat or sheep 60, 61. The nasal epithelium reported by these
publications was found the be intact after exposure to such a high concentration of
G8/10MD. However, as seen in the in vitro studies on Calu-3 cells, SEN containing
G8/10MD exhibited concentration-dependent toxicity. But the SEN containing G8/10MD
(0.8%) can significantly (p<0.05) enhance the permeability of insulin without noticeable
cytotoxicity or the irreversible opening of the tight junctions. In this Chapter, ex vivo
method was used to further evaluate SEN containing G8/10MD for its toxicity and
permeation enhancing effect on the bovine nasal mucosa.
The nasal mucosa from various animals including bovine, porcine, caprine, and
ovine have been used for ex vivo permeation study across nasal route 11. Among these
animals, bovine nasal mucosa has been widely used due to the similarity to humans in
terms of the epithelial types, aminopeptidase activity which is necessary for the stability
of the therapeutic peptides delivered intranasally, and the presence of both transcellular
and paracellular transports in the excised mucosa 62, 63. Therefore, bovine nasal mucosa
was selected as an ex vivo model in the current study.
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The objective of this chapter was to select the proper concentration of SEN
containing G8/10MD for the further in vivo study by investigating the permeationenhancing effect and nasal ciliotoxicity of the SEN on insulin.
3.1 Materials
Ammonium hydroxide solution and human insulin (27.5 IU/mg) were purchased
from Sigma-Aldrich, Co. (St. Louis, MO, USA). Acetic acid (Glacial) and
Kolliphor®RH40 was purchased from Millipore Sigma (St. Louis, MO, USA).
Acetonitrile ≥ 99.8% for HPLC, Ethanol (100%, reagent grade for histology), Eosin Y
solution (1%), Haematoxylin solution Gill II, methanol ≥99.8% for HPLC, Isopropyl
alcohol (IPA), Phloxine B solution (1%), Roswell Park Memorial Institute (RPMI)-1640,
Trifluoroacetic acid (TFA), Xylene, and Permount™ Mounting Medium were purchased
from VWR (West Chester, PA, USA). Bovine nasal mucosa was purchased from
Lampire Biological Inc. (Everett, PA, USA). Captex®8000 (G8T, C8 Triglycerides) and
Capmul® MCM (G8/10MD, C8/10 Mono- and Diglycerides) were kindly gifted by
Abitec Corporation (Janesville, WI, USA). Dulbecco’s Phosphate-Buffer Saline, pH 7.0
with calcium/magnesium was purchased from Hyclone (Logan, UT, USA). Human
Insulin ELISA Kit was purchased from Crystal Chem (Elk Grove Village, IL, USA).
3.2 Methods
3.2.1 Preparation and Characterization of Insulin in SEN
The preconcentrate of SEN was prepared by mixing G8T, G8/10MD, and
Kolliphor®RH40 at 1:1:2 weight ratio and being shaken in a MaxQ™ 4000 Benchtop
Orbital Shaker (Thermo Scientific™, USA) for three hours (300 rpm, 37 °C). The insulin
stock solution (1 mg/mL in PBS) was prepared. Then, the preconcentrate was diluted
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with the insulin solution to form 30SEN, 20SEN, and 10SEN (containing 30%, 20%, and
10% (w/v) of preconcentrate, respectively) with the same concentration of insulin at 10
IU/mL.
The droplet sizes and Zeta potential of SENs were measured by a Zetasizer®
Nano ZS (Malvern Instrument Inc., USA). SENs containing insulin were diluted with
methanol and the insulin content was quantified by using HPLC (n=3). The concentration
of insulin in each SEN was used as the initial concentration to calculate the percentage
transport of insulin in the permeation study.
3.2.2 HPLC Assay
The HPLC assay of insulin was carried out on an Agilent 1260 series UV detector
with C18, 5 μm, 4.6 X 150 mm as the stationary phase. An isocratic method was used,
and the experiment was run at room temperature. The mobile phase, consisting of 70%
(v/v) deionized (DI) water, 30% (v/v) acetonitrile and 0.1% (v/v) trifluoroacetic acid
(TFA), was pumped at flow rate of 1 mL/min over 10 min. The injection volume was 20
μL and analyzed at a wavelength of 214 nm. The retention time was at 3.6 min and the
peak area was used to quantify the insulin.
3.2.3 Preparation of Nasal Mucosa
Bovine nasal tissues from both the posterior and anterior regions (Figure 12) were
obtained from freshly-slaughtered bovine. The tissues were stripped from the lateral
cartilage and transported to the laboratory in ice-cold RPMI-1640. The mucosal tissues
were carefully cut and excised from the submucosa layer with a scalpel. The mucosal
specimen with a thickness of 300 µm (measured by Vernier caliper) and the surface area
of 3.53 cm2 (1.5 cm diameter) was used for the permeation study.
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3.2.4 Ex vivo Permeation Study
The Franz diffusion chambers (Figure 13) used in the study had an effective
diffusion area of 1.27 cm2 (0.9 cm diameter) and a receptor volume of 5.0 ± 0.2 mL. The
diffusion cells were preincubated at 37 ˚C for 15 min by using the Corio CD-BC4, a
constant circulation water bath (Julabo, USA). PBS (five mL, at 37 ˚C) was added to the
receptor chambers and continued stirring using a magnetic bar. The excised mucosa was
rinsed once with PBS and immediately mounted on the diffusion cells with the mucosal
surface facing the donor chamber. PBS (one mL, at 37 ˚C) was added in the donor
chamber and stabilized for 10 min. Then, the PBS was gently removed and the test
formulations (one mL, at 37 ˚C) were placed. The temperature was controlled at 37±1˚C.
The samples (200 µL) were taken from the receptor chamber at 30, 60, 90, 120 min and
replaced with fresh PBS. The samples were diluted with DI water for 200 times and
analyzed with an Enzyme-linked immunosorbent assay (ELISA). Fresh DI water was
analyzed for background reading. Insulin solution in PBS (10 IU/mL) was used as the
control. The permeation of insulin was calculated as the percentage of the initial
concentration added to the donor chamber.
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Figure 12 Locations of the collected tissues: (1) Posterior region; (2) Anterior region
which is approximately 3-inch depth from the external opening.

Exposed area
Donor chamber

Nasal mucosa
Sampling port
0.9 cm

Nasal
ciliotoxicity
study

Water
circulation
Receiver
chamber
Stirrer

Figure 13 Schematic representation of the Franz diffusion cell used in the ex vivo
permeation study across bovine nasal mucosa, and the exposed area on the nasal mucosa
which was used for nasal ciliotoxicity study.
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3.2.5 ELISA Assay Procedure
In each well, HRP labeled antibody solution (100 µL) was added followed by
samples (25 µL) and mixed well by repeated pipetting. The microplate was covered with
the plate sealer and incubated for two hours at 37 ˚C. After incubation, the solution in
each well was removed and washed with wash buffer (300 µL) for four times. In each
wash, any remaining solution in the well was removed by inverting and tapping the plate
firmly on a clean paper towel. The plate was then kept in the darkroom to protect from
light. The substrate solution (100 µL) was added to each well and incubated in dark for
15 min at room temperature. The stop solution (100 µL) was added to stop the reaction
and the absorbance at 450 nm was immediately analyzed by a spectrophotometer
Glomax® Discover microplate reader (Promega, USA). The concentration of insulin in
samples was calculated according to the standard curve.
3.2.6 Nasal Ciliotoxicity Study
3.2.6.1 Formalin Fixation and Paraffin Embedding
The exposed area (Figure 13) of the mucosa after 2-h treatment with the
formulations were cut and fixed in 10% formalin for 24 hours. The fixed tissues were
trimmed into appropriate size and dehydrated according to the procedure in Table 8. The
dehydrated tissues were embedded in paraffin. Thin sections (7 µm) of tissue were
prepared by a microtome. The mucosa treated with insulin solution in phosphate buffer
saline (PBS) and 20% Isopropyl alcohol (IPA) were considered as the negative and
positive control, respectively.
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Table 8 Tissue dehydration and infiltration procedure.
Step

Solutions

Submerging time (h)

1

Ethanol (70%)

2

2

Ethanol (80%)

2

3

Ethanol (90%)

2

4

Ethanol (100%)

2

5

Ethanol (100%)

2

6

Ethanol (100%))

2

7

Xylene

2

8

Xylene

2

9

Paraffin (melted at 60˚C)

1

10

Paraffin (melted at 60˚C)

1
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3.2.6.2 Hematoxylin and Eosin (H&E) Staining
The Eosin-Phloxine solution was prepared by mixing 11% Eosin solution, 1.5%
Phloxine B solution, 87% Ethanol (95%), and 0.5% Glacial Acetic acid. The thin sections
were mounted on the glass slide and stained in hematoxylin and eosin solutions following
the solutions and time described in Table 9. The stained sections were observed and
photographed by Nikon Eclipse Ts2R microscope with Nikon DS-Qi2 camera.
3.2.7 Data Analysis
The data are expressed as mean ± standard deviation (n=3). The transport of
insulin was analyzed by student’s t-test to compare the difference between SENs and
insulin solution. The difference was considered significant when p<0.05.

68

Table 9 Hematoxylin and Eosin (H&E) staining procedure.
Step

Solutions

Submerging time
(min)

1

Xylene

5

2

Xylene

5

3

Xylene

5

4

Ethanol (100%)

2

5

Ethanol (95%)

2

6

Ethanol (70%)

2

7

Ethanol (30%)

2

8

Distilled water

1

9

Haematoxylin solution Gill II

10

10

Distilled water

1

11

Tap water

1

12

Ethanol (70%) and Ammonium hydroxide (1%)

1

13

Tap water

1

14

Distilled water

2

15

Ethanol (70%)

2

16

Eosin-Phloxine solution

2

17

Ethanol (95%)

2

18

Ethanol (100%)

2

19

Ethanol (100%)

2

20

Ethanol (100%)

2

21

Xylene

2

22

Xylene

2

23

Xylene

2
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3.3 Results and Discussion
3.3.1 Preparation and Characterization of Insulin in SEN
Table 10 shows the mean droplet size and zeta potential of the blank SENs at
different dilutions. The mean droplet size and zeta potential of the SENs were
approximately 30 nm and -2 mV, respectively, indicating the concentration of
preconcentrate in the SEN did not change the zeta potential and droplet sizes. The insulin
content added in the SENs analyzed by HPLC was 9.2-9.9 IU/mL.
3.3.2 Ex vivo Permeation and Nasal Ciliotoxicity Studies
Figure 12 shows the locations of bovine nasal tissues that were collected to
perform the studies. Two regions included the anterior tissue (approximately 3-inch depth
from the external opening) and the posterior tissue located in the nasal cavity.
Figure 14 demonstrates the difference between the mucosa collected from the
anterior and posterior regions. The epithelial layer of the anterior tissue was
approximately 3-fold thicker than the posterior tissue.
The delivery of liquid formulation through the nasal route has been achieved by
using the liquid nasal spray. The currently available liquid spray devices include
traditional liquid spray device and Bi-directionalTM delivery device. Djupesland et al.
explained that the traditional liquid spray provides the greatest deposition in the lower
anterior region of the nasal cavity, whereas the deposition provided by the bidirectionalTM liquid delivery device was greatest in the upper posterior region of the nasal
cavity (Figure 15) 64.
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Detailed examination of the human nasal epithelium shows that the anterior and
posterior regions of the nasal cavity are lined with the different epithelial types and
exhibited unequal thickness. One-third of the human epithelium consists of stratified
squamous epithelium located in the anterior region (nasal vestibule and atrium). The
posterior of the nasal cavity covering two-third of the epithelium is called respiratory
region lining with pseudostratified columnar ciliated epithelium which is a single layer of
cells appearing to be stratified. The permeability of the drug was highest across the
respiratory region > atrium > nasal vestibule 65. However, in literature, the differences in
epithelium types and thickness between these two regions have been somehow neglected
during the determination of toxicity and permeation-enhancing effect of the formulation.
As a result, the mucosae in both regions were used in the current study.
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Table 10 The droplet size, zeta potential, and content of G8/MD in SENs (mean ± S.D,
n=3).
Formulation

G8/10MD

Droplet

Polydispersity

Zeta potential

(%)

Size (nm)

Index

(mV)

30SEN

7.5%

32 ± 9

0.068 ± 0.021

-1.58 ± 0.86

20SEN

5%

30 ± 7

0.055 ± 0.013

-2.50 ± 0.77

10SEN

2.5%

30 ± 7

0.074 ± 0.022

-1.52 ± 0.75
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(A)

(B)

Figure 14 The differences of nasal mucosa between anterior and posterior regions. (A)
Anterior (stratified squamous epithelial cells); (B) Posterior (pseudostratified ciliated
columnar cells). Scale bar is 100 µm.
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Figure 15 Schematic of the sagittal section of the nasal cavity. Top: different sections of
the nasal cavity: (A) nasal vestibule; (B) atrium; (C) respiratory region; (D) olfactory
region; and (E) nasopharynx, reported by Djupesland et al. 64. Bottom: Gamma camera
image information (logarithmic “hot iron” intensity scale) from the nasal cavity is
superimposed on the corresponding sagittal MRI section. The images are from the same
object and present deposition 2 min after delivery using (Left) a traditional liquid spray,
(Right) Bi-DirectionalTM liquid spray device, reported by Arora et al. 65.

74

3.3.2.1 Posterior Region
Figure 16A shows the cumulative transport of insulin across the posterior mucosa.
The 2-h cumulative transport of insulin in 30SEN and 20SEN were significantly (p<0.05)
higher than insulin in PBS (0.74 ± 0.21% and 0.37 ± 0.01% vs 0.15 ± 0.01%), whereas
insulin in 10SEN showed the similar transport as compared to insulin solution (0.18 ±
0.03% vs 0.15 ± 0.01%). These indicate that the permeation-enhancing effect of SEN
containing G8/10MD was concentration-dependent which was expected from the in vitro
permeation study in Chapter 2. However, the concentration of the preconcentrate in SEN
which can significantly (p<0.05) increase the transport of insulin was 20% (containing
5% G8/10MD) which was 25-fold higher than the concentration used in the in vitro
studies (0.8% SEN containing 0.2% G8/10MD).
The microscopic images of posterior mucosa pretreated with insulin solution
(negative control), insulin in SENs, and 20% IPA (positive control) were shown in Figure
17-18. The intact pseudostratified columnar epithelium was observed in the mucosa
pretreated with 10SEN and insulin solution (Figure 17A-B). The epithelium pretreated
with 20SEN (Figure 17C) was observed to be thinner as compared to the negative
control, but the layer of epithelium remained observable. The epithelium pretreated with
30SEN was found to be damaged (Figure 17D) indicating higher toxicity than 20SEN,
but no inflammatory cells were observed. The epithelium pretreated with the positive
control exhibited an increase in inflammatory cells with the damaged epithelium (Figure
18). The nasal ciliotoxicity of SEN containing G8/10MD was also concentrationdependent which was correlated to the in vitro cytotoxicity in Chapter 2.
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3.3.2.2 Anterior Region
Although 30SEN exhibited the highest permeation-enhancing effect on insulin
across posterior mucosa, this concentration caused damage to the posterior epithelium.
Therefore, the highest concentration used in the anterior mucosa was 20SEN. The 2-h
cumulative transport of insulin achieved by 20SEN was significantly (p<0.05) increased
from insulin solution (0.45 ± 0.12% vs 0.12 ± 0.01%). The 2-h cumulative transport of
insulin from insulin in 20SEN, 10SEN, and solution across the anterior mucosa (Figure
16B) were similar to the posterior mucosa (p > 0.05). However, at 90 min, the transport
of insulin across anterior mucosa was significantly (p<0.05) lower than the transport
across posterior mucosa (0.15 ± 0.04% vs 0.30 ± 0.06%) (Figure 16), indicating the delay
in permeation enhancement of SEN. This may be due to the thicker layer of the
epithelium in the anterior region making it more difficult for SEN to enhance the
transport of insulin.
Figure 19 shows the nasal ciliotoxicity of the mucosa. The intact epithelium was
also observed with the mucosa pretreated with 10SEN and insulin solution as similar to
the posterior region. However, the increase in inflammatory cells was observed in the
epithelium exposed to 20SEN (Figure 19C).
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Figure 16 Cumulative transport of insulin across bovine nasal mucosa located in (A)
posterior region; (B) anterior region, following ■) insulin solution; (△) i.n. insulin in
10SEN; (▲) i.n. insulin in 20SEN; (✕) i.n. insulin in 30SEN (mean ± SEM; n=3). *:
Significantly higher than insulin solution and insulin in 10SEN (p<0.05).
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(A)

(B)

(C)

(D)

Figure 17 Nasal mucosa from the posterior region exposed to insulin loaded in (A)
phosphate buffer saline (negative control); (B) 10SEN (containing 2.5% G8/10MD); (C)
20SEN (containing 5% G8/10MD); (D) 30SEN (containing 7.5% G8/10MD). Scale bar is
100 µm.
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Figure 18 Nasal mucosa from the posterior region exposed to 20% IPA (positive
control). Scale bar is 100 µm. Yellow arrows indicate the inflammatory cells.
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(A)

(B)

(C)

Figure 19 Nasal mucosa from the anterior region exposed to insulin loaded in (A)
phosphate buffer saline; (B) 10SEN (containing 2.5% G8/10MD); (C) 20SEN (containing
5% G8/10MD). Scale bar is 100 µm. Yellow arrows indicate inflammatory cells.

80

3.4 Trends and Limitations
Bovine nasal mucosa has been reported for its similarity to human nasal
epithelium. However, the limitation of the excised nasal mucosa is the thickness. Human
nasal epithelium has the thickness of 50 µm, but the thinnest bovine nasal mucosa which
can be prepared is approximately 300 µm. It was observed that the thinner layer (< 300
µm) caused the leakage of formulation from donor to receiver chamber of Franz diffusion
cell. Therefore, the nasal mucosa used in this Chapter included both epithelium and
subepithelial layers which caused the insulin detected in the receiver chamber did not
represent the actual absorption of insulin in the blood circulation. Once the insulin
transported across the epithelium, the insulin molecule should be absorbed to the blood
circulation through the abundant vascular networks presented in the subepithelial layers,
rather than transport across these layers to the receiver chamber. As the result, even
though the transport of insulin was significantly (p < 0.05) increased only by 20SEN, the
lower concentration of SEN may be effective in the in vivo study.
In addition to the permeation result, the nasal ciliotoxicity determined from
histological study can only represent the toxicity of the epithelial layer. The effect on
cilia cannot be concluded because there is no cilia observed in any samples including the
untreated epithelium which may due to the processing time from when animals are
slaughtered to the experiment.
3.5 Conclusion
The 2-h transport of insulin across the nasal mucosa from both anterior and
posterior regions was significantly (p<0.05) enhanced by 20SEN, while 10SEN did not
enhance the transport of insulin. After 2-h treatment, the 20SEN caused minimum
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nasociliotoxicity on the bovine nasal mucosa, while no toxicity was observed with the
10SEN. Therefore, 20SEN was selected as the highest concentration in the in vivo study.
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CHAPTER 4
IN VIVO PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES OF
INSULIN IN SEN CONTAINING G8/10MD ON STREPTOZOTOCIN-INDUCED
DIABETIC RATS
Various animal models have been used for the in vivo study for the nasal delivery
of insulin. As shown in Table 11, there are differences between interspecies including
body weight, nasal volume, nasal surface areas, and epithelium types. However, due to
the easy accessibility and suitability for the early-stage experiment, rats have been widely
used by more than 50% of the publications as the first mammalian species for the nasal
delivery system. Two types of epithelium are lining in the nasal cavity of rats. The nasal
septum is covered by ciliated pseudostratified columnar epithelium and the nasoturbinate
is covered with ciliated pseudostratified cuboidal epithelium. The tight junctions are
presented throughout the nasal cavity 66. It can be seen that the rat’s nasal cavity is a good
representation of the posterior region of the human nasal cavity due to the similarity in
the epithelial type 65.
Diabetic induction in rats has been widely used as a model for diabetic treatment.
The study on diabetic rats helps to predict the therapeutic efficacy of the formulation in
the disease conditions e.g. blood glucose level, malfunction of the pancreas, etc. which
better represent diabetic patients. Various types of diabetic induction have also been
reported in the literature including spontaneous autoimmune, genetically induced, virally
induced, and chemical induction including Alloxan and Streptozotocin (STZ), etc. 67.
STZ has a similar structure to glucose which can enter the pancreatic beta-cell through
Glut-2 transporter and consequently inhibits insulin production to induce type I diabetes
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67, 68

. Many publications indicate that the high dose STZ injection (0.2 mmol/kg body

weight) is the simplest model with the high success rate and low implications to induce
diabetes which is suitable for testing the new formulations of insulin 69-72. Therefore, the
high dose STZ injection was selected as the method to induce diabetes in this study.
The objective of the current chapter is to investigate the effect of SEN
concentration on the intranasal absorption of insulin by using STZ-induced diabetic rats
as an animal model. The highest concentration of SEN used in this study was 20SEN
which was selected based on the ex vivo studies in Chapter 3.
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Table 11 Differences of nasal histology among various species 16, 65, 66, 73-79.
Species

Average

Nasal

Body

Volumea Surface Volumeb

Weight

(mL)

70

Areaa

Delivery Epithelium Types
(mL)

(cm2)

(kg)
Man

Nasal

15-20

160

0.1-0.3

Stratified squamous epithelium;
Ciliated pseudostratified
columnar epithelium

Monkey 7

8

62

0.1-0.3

Stratified squamous epithelium;
Ciliated pseudostratified
columnar epithelium

Dog

10

20

221

0.1-0.3

Stratified squamous epithelium;
Ciliated pseudostratified
columnar epithelium

Sheep

40-60

114

327

0.3-0.6

Stratified squamous epithelium;
Ciliated pseudostratified
columnar epithelium

Rabbit

2-4

6

61

0.1-0.25

Stratified squamous epithelium;
Ciliated pseudostratified
columnar epithelium

Rat

0.25

0.4

14

0.02-0.1

Ciliated pseudostratified
columnar epithelium;
Ciliated pseudostratified
cuboidal epithelium

Mouse
a

0.03

0.03

2.8

N/A

: both nostrils; b: one nostril.
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N/A

4.1 Materials
Captex®8000 (G8T, C8 Triglycerides) and Capmul® MCM (G8/10MD, C8/10
Mono- and Diglycerides) were kindly gifted by Abitec Corporation (Janesville, WI,
USA). Citrate buffer solution (0.5 M, pH 4.5), Sodium lauryl sulfate, Formalin (10%),
Acetonitrile ≥ 99.8% for HPLC, Ethanol (100%, reagent grade for histology), Eosin Y
solution (1%), Haematoxylin solution Gill II, methanol ≥99.8% for HPLC, Isopropyl
alcohol (IPA), Phloxine B solution (1%), Trifluoroacetic acid (TFA), Xylene, and
Permount™ Mounting Medium were purchased from VWR (West Chester, PA, USA).
Dulbecco’s Phosphate-Buffer Saline, pH 7.0 with calcium/magnesium was purchased
from Hyclone (Logan, UT, USA). Ammonium hydroxide solution and Human insulin
(27.5 IU/mg) was purchased from Sigma-Aldrich, Co. (St. Louis, MO, USA). Human
Insulin ELISA Kit was purchased from Crystal Chem (Elk Grove Village, IL, USA).
Isoflurane was purchased from Covetrus (Portland, ME, USA). Acetic acid (Glacial) and
Kolliphor®RH40 was purchased from Millipore Sigma (St. Louis, MO, USA).
Streptozotocin was purchased from Adipogen®Life Sciences (San Diego, CA, USA).
RDO rapid decalcifier was purchased from Apex Engineering products corporationTM
(Aurora, IL, USA).
4.2 Methods
4.2.1 Preparation of SEN Formulations
The preconcentrate of SEN consisted of G8T, G8/10MD, and Kolliphor®RH40 at
1:1:2 weight ratio. This preconcentrate was diluted 5, 10, and 20-time with phosphate
buffer saline (PBS) to make 20SEN, 10SEN, and 5SEN (containing 20%, 10% and 5% of
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the preconcentrate respectively). Insulin was added into the aqueous phase of SENs at the
concentration that can provide 3 IU/kg at 50-µL dose volume.
4.2.2 Induction of Diabetes in Rats
The male Sprague Dawley rats (200-250 g) were fasted with water ad libitum for
12 hours before the diabetic induction. Streptozotocin (STZ) solution in 10 mM ice-cold
citrate buffer at pH 4.5 was freshly prepared and covered with foil to protect from light.
The fasted rats were given a single intraperitoneal (i.p.) injection of this STZ solution at
0.2 mmol/kg body weight. After injection, all the rats were allowed to stabilize with free
access to food and water ad libitum. The fed blood glucose was measured 48 hours after
STZ injection by using AimStrip® Plus Blood Glucose Meter (Germaine Laboratories,
TX, USA) to determine the diabetic condition. Only the rats with blood glucose levels
higher than 300 mg/dL are considered diabetic and were used in the study.
4.2.3 Administration of Formulation in Diabetic Rats
Streptozotocin-induced diabetic rats (250-300 g) were randomly divided into
seven groups (n=3-4) and administered with the formulations according to Table 12.
Group I was received insulin solution in PBS (1 IU/kg) by subcutaneous (s.c.) injection
which was used as the control group for the evaluation of bioavailability (BA) and
pharmacodynamic availability (PA) of the intranasal (i.n.) groups. Groups II-IV were
intranasally administered with the test formulations including insulin in 20SEN, 10SEN,
and 5SEN, respectively. Group V was received i.n. administration of insulin solution
containing sodium lauryl sulfate (SLS) which was used as the positive control for nasal
toxicity. Groups VI and VII were received insulin solution and phosphate buffer saline
(PBS), respectively, by the i.n. administration, and were used as the negative controls.
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The rats were fasted with water ad libitum for 12 hours prior to the experiment.
The fasted rats were anesthetized by 3% isoflurane for a few mins and kept under 2%
isoflurane for 20-30 min to stabilize the blood glucose level. The stabilized glucose level
was used as initial blood glucose (100%). Then, the treatment was given. The nasal
administration was done on the right nasal cavity using a micro-syringe connected to gelloading tips. Then, 1.5% isoflurane was used to maintain the unconscious effect for 4
hours.
After the administration of the formulation, blood samples (200 µL) were
collected by tail tipping at 5, 15, 30, 45, 60, 90, 120, 180, and 240 min into heparincoated microcentrifuge tubes. The blood glucose level was also measured using the
glucose meter at 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 min. After the final sampling
at 240 min, the animals were euthanized by carbon dioxide inhalation. The head was
collected for histological study to evaluate the toxicity of the formulation. The blood
samples were centrifuged at 10,000 g for 5 min. The plasma was separated and stored at 20˚C until further analysis. The plasma concentration of insulin was determined by
Human-insulin ELISA kits (Crystal Chem, IL, USA) following the method explained in
Chapter 3.
4.2.4 Pharmacokinetic and Pharmacodynamic Analysis
Standard non-compartmental analysis was performed on Pheonix Winnolin 8.2
(Certara USA, Inc., NJ, USA) for the determination of the pharmacokinetic and
pharmacodynamic parameters. The area above the curve (AAC) of the intranasal groups
(Group II-VI) was calculated by using the blood glucose level from the intranasal
administration of PBS (Group VII) as a baseline.
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With S.C. group as the reference, the relative pharmacological availability (PA)
and relative bioavailability (BA) of the intranasally administered insulin were calculated.
The relative PA was calculated by the following equation
AACf(0−240min) /Dosei.n.

%𝑃𝐴 = AAC

s.c.(0−240min) /Doses.c.

× 100,

where, AACf is the area above the curve of glucose reduction-time curve of formulation or
buffer group; AACs.c. is the area above the curve of glucose reduction-time curve of
subcutaneous injection group, Dosei.n. is the intranasal delivery dose (3 IU/kg) and Doses.c. is
the subcutaneous

delivery dose (1 IU/kg).

The relative BA was calculated by the following equation:
AUCf(0−240min) /Dosei.n.

%B𝐴 = AUC

s.c.(0−240min) /Doses.c.

× 100,

where, AUCf is the area under the insulin-time curve of formulation or buffer group; AUCs.c.
is the area under the curve of the insulin-time curve of subcutaneous injection group, Dosei.n.
is the intranasal delivery dose (3 IU/kg) and Doses.c. is the subcutaneous delivery dose (1
IU/kg).

4.2.5 Histological Study
The treated rats were decapitated, and the specimens were fixed in formalin
solution (10%). After fixation, the skin of the specimens was removed prior to the
decalcification. The specimens were decalcified with RDO rapid decalcifier containing 59% hydrochloric acid for 4 hours. The nasal cavity from section II was excised and
briefly rinsed with DI water66. The excised cavity was kept in formalin solution for
another 24 hours. Then, the nasal cavity was undergone dehydration and paraffin
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embedding according to the procedure described in Section 4.2.7.1. Thin sections (7 µm)
of tissue were cut by using a microtome and stained with H&E solutions as described in
Section 4.2.7.2. The stained sections were observed and photographed by Nikon Eclipse
Ts2R microscope with Nikon DS-Qi2 camera.
4.2.6 Statistical Analysis
The values were expressed as mean ± standard error of the mean (SEM).
Statistical analysis was performed by One-way ANOVA followed by Tukey’s HSD Posthoc test. The difference was considered significant when p<0.05.
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Table 12 Details of formulations and their administrations to each animal group.
Route of
Group

Insulin

Formulation

Volume
Administration Dosing

I

Insulin solution

Subcutaneous

1 IU/Kg

500 µL

II

Insulin in 20% SEN

Intranasal

3 IU/Kg

50 µL

Intranasal

3 IU/Kg

50 µL

Intranasal

3 IU/Kg

50 µL

(20SEN)
III

Insulin in 10% SEN
(10SEN)

IV

Insulin in 5% SEN
(5SEN)

V

1% Sodium lauryl sulfate

Intranasal

3 IU/Kg

50 µL

VI

Insulin solution

Intranasal

3 IU/Kg

50 µL

VII

Phosphate buffer saline

Intranasal

0 IU/Kg

50 µL
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4.3 Results & Discussion
4.3.1 Pharmacodynamic Analysis
The blood glucose level of the rats before the experiment were shown in Table 13.
After 48 hours of STZ injection, all the rats became diabetes with the average blood
glucose level of 368.40 ± 14.42 mg/dL. The diabetic condition in rats was maintained
until the day of the experiment.
The hypoglycemic effect from various concentrations of SENs was shown in
Figure 20. The average stabilized blood glucose before dosing was 228.16 ± 16.47 mg/dL
and was used as the initial blood glucose (Table 13). The i.n. administration of insulin in
20SEN, 10SEN, and 5SEN significantly (p<0.05) reduced blood glucose levels in
diabetic rats as compared to insulin solution. The maximum reduction in blood glucose
level was observed at 90 min after dosing. The highest blood glucose reduction was
achieved by 20SEN followed by 10SEN and 5SEN, resulted in the blood glucose level of
55.39±2.54%, 73.89±2.79%, and 79.83±8.64% of initial blood glucose, respectively. The
hypoglycemic effect lasted until 240 min from 20SEN and 10SEN, and until 120 min
from 5SEN.
Table 14 shows the relative PA as compared to s.c. injection of insulin solution (1
IU/kg). The relative PA achieved by 20SEN, 10SEN, and 5SEN were 79.3 ± 9.4%, 58.4
± 7.7%, and 42 ± 13.0%, respectively, which were significantly (p<0.05) higher than the
solution form (1.4 ± 6.1%). The relative PA by 20SEN was also significantly (p<0.05)
higher than the SLS solution (33.9 ± 8.9%).
The maximum blood glucose reduction achieved by insulin in SLS solution was
observed at 45 min and resulted in the blood glucose level of 54.66±2.87% of the initial
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blood glucose, which was similar to the maximum glucose reduction achieved by 20SEN.
However, after 45 min, the glucose level bounced back at a much faster rate as compared
to insulin in the SENs. SLS has been known to cause severe damage to the nasal mucosa
80

. Therefore, the glucose reduction at the beginning of the study could be the result of the

high amount of insulin rapidly absorbed across those severely damaged nasal mucosae.
The rats which were intranasally administered with insulin solution or blank PBS
showed the significant (p<0.05) increase in blood glucose level which continuously
increased to about 160% at the end of the experiment (240 min). These indicate that the
administration of the liquid formulation into the nasal cavity could trigger the increase in
blood glucose level which was correlated with several publications 81-85. Based on these
results, the increase in blood glucose by i.n. PBS was taken into consideration when the
AAC for PA evaluation was calculated for the other intranasal groups.
To confirm the effect of isoflurane on blood glucose level, the other three rats
were tested with isoflurane (1.5%) alone, without intranasal administration of liquid, for
four hours. The result showed that there was a slight reduction in blood glucose level at
90 min, resulting in the blood glucose level of 85.52 ± 0.42% of initial blood glucose.
And after 90 min, the blood glucose level returned to about 100% and stable until the end
of the experiment. Nishino et al. reported that the use of isoflurane at low concentration
(1-3%) did not produce any reflex responses from respiratory, laryngeal, and tracheal as
well as no change in tracheal smooth muscle tone86. This indicates that the use of 1.5%
isoflurane had a minimum effect on the blood glucose level and drug absorption across
the nasal route.

93

Table 13 Blood glucose level of the rats before the experiment (mean ± SEM, n = 25).
Conditions

Blood Glucose
Level (mg/dL)

After 48-hour of STZ injection with free access to food and water

368.40 ± 14.42

The day before the experiment with free access to food and water

363.04 ± 8.67

After fasting for 12-14 hours with free access to water

185.92 ± 13.55

After fasting for 12-14 hours and then anesthetized by 3%

228.16 ± 16.47

isoflurane and stabilized for 20-30 min with 2% isoflurane (Initial
blood glucose)
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4.3.2 Pharmacokinetic Analysis
Figure 21 exhibits the plasma insulin-time profiles following various
formulations. The 20SEN, 10SEN, and 5SEN resulted in the highest plasma insulin
concentration (Cmax) of 247.2±12.2, 101.3±8.0, and 53.2±17.6 µU/mL, respectively,
which were significantly (p<0.05) higher than the solution form (13.5±6.7 µU/mL). The
Cmax by 20SEN and 10SEN were also significantly (p<0.05) higher than the Cmax by the
s.c. injection (68.5±31.3 IU/mL). The Tmax of insulin in 5SEN was found at 5 min,
while Tmax of insulin in 10SEN and 20SEN was approximately 8 and 12 min, respectively
(Table 14).
Table 14 also shows the relative BA as compared to s.c. injection of insulin
solution (1 IU/kg). The 20SEN, 10SEN and 5SEN achieved 37.9±7.6%, 19.3±5.4%, and
8.8±6.4% relative bioavailability (BA) as compared to the s.c. injection, which were 8.5-,
3.8-, and 1.2-fold higher than that by the solution, respectively. The relative BA of i.n.
insulin in 20SEN was also significantly higher (p<0.05) than insulin in 5SEN. The insulin
in SLS resulted in a relative BA of 24.1 ± 3.6% which was between those by the 20SEN
and 10SEN.
The SENs containing G8/10MD exhibited the capability to enhance insulin
absorption across the nasal route resulted in the significantly increased relative PA and
relative BA. The permeation enhancing effect of SEN containing G8/10MD was found to
be concentration-dependent. The 20SEN which was the highest concentration in the study
showed the highest relative PA and relative BA among all the formulations.
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4.3.3 Histological Study
Figure 22-24 show the vertical cross-sections of the rat nasal cavities including
the nasal septum which connects two-side nasal cavities, olfactory epithelium, and
respiratory epithelium. The nasal epithelial throughout the cavity exposed to HI solution,
10SEN and 20SEN were intact (Figure 22A-C). There was no compromise in the
integrity of olfactory epithelium and respiratory epithelium observed on both sides of the
cavity as shown in Figure 23A-C and Figure 24A-C, respectively. It can be concluded
that there was no noticeable nasal ciliotoxicity caused by the SEN containing G8/10MD
from the studied concentrations.
Figure 22D indicates the ciliotoxicity caused by SLS, positive control. Both
olfactory and respiratory epithelial on the right cavity (treated side) were severely
damaged by SLS solution, whereas the epithelium on the left cavity was intact until the
respiratory epithelium near the dorsal nasal meatus which was also damaged (Figure 23D
and Figure 24D). This may be due to the distribution of the solution into the untreated
side.
4.4 Trends and Limitations
The results from the present study showed that i.n. insulin in 10SEN (90% of
PBS) and 20SEN (80% of PBS) had the relative BA of 19.3 ± 5.4% and 37.9 ± 7.6%
which were 5-fold and 9.5-fold higher than i.n. insulin solution, respectively. With the
solubility of insulin in PBS (55 IU/mL), Human insulin can be loaded in 10SEN and
20SEN upto 49.5 and 44 IU/mL, respectively. To achieve the 50 IU dose for a male
patient (75 kg), approximately 1 mL of the formulation is required (0.25 mL per puff, and
4 puffs per dosing). This indicates that both 10SEN and 20SEN are applicable to apply in
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human. However, the current study only shows that a single dose of SEN does not cause
any noticeable toxicity. Therefore, the long-term toxicity of the formulated SEN cannot
be concluded and will require further study.
Sintov et al. reported that the i.n. insulin in w/o SEN improved the relative BA of
21.5% in diabetic rabbits, while o/w SEN did not improve BA of insulin. The w/o SEN
contained 20% of aqueous and 80% of lipid phase including surfactants etc. By
considering 20% of water in the formula, the maximum loading capacity of insulin would
be about 10-11 IU/mL which may not be sufficient for the human dose. Also, such a high
percentage of the lipid phase may cause several problems after nasal delivery 17. Another
study reported by Mitra et al. have used both o/w and o/w lipid micelles. However, w/o
micelles did not show any improve in the PK parameters which was in contrast with w/o
SEN reported by Sintov et al. And the insulin in o/w micelles only increased the AUC0-120
for 1.5-fold as compared to insulin in buffer at 5 IU/kg 87. It can be seen that the
developed SEN containing FAME can overcome these issues with the higher
improvement in relative BA.
In addition to the emulsion system, the most successful delivery techniques for
intranasal delivery of insulin have been cyclodextrin and cationic polymer, chitosan. The
use of cyclodextrin for intranasal delivery of insulin has been studied for decades 88.
Various types of cyclodextrin have been developed to overcome their toxicity and to
improve their drug loading capacity. The most successful cyclodextrin system was
insulin-loaded dimethyl-β-cyclodextrin which resulted in 108% relative BA as compared
to s.c. injection in rats without any toxicity observed. However, the relative BA of the
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same formulation was found to be 0% in rabbits and humans 89. The correlation between
animal model and human for cyclodextrin was found to be very low.
Chitosan is a cationic polysaccharide which has been used to enhance insulin
absorption across the nasal route by forming nanoparticles or as a permeation enhancer.
Nanoparticles for insulin did not appear to effectively improve insulin absorption and the
insulin-loading capacity remained limited, while the addition of chitosan (0.5%) into
insulin solution improved the relative BA to 48% in rats and 4% in sheep as compared to
S.C 15, 75, 90. The permeation enhancing effect of chitosan was concentration dependent
and the mechanism of enhancement was the reversible interaction between chitosan with
the tight junctions due to the positive charge of chitosan at the pH below its pKa of 6.5.
Illum et al. reported many clinical trials (> 700 human volunteers and patients) have been
on nasal formulations containing chitosan, but there are no nasal products reaching the
market either for small molecules to proteins like insulin 15. One of the possible reasons is
that the charge of the mucus layer on the epithelium is also a negative charge which can
bind with chitosan before the chitosan molecule can interact with the tight junctions of
the epithelium layer. However, SEN with the size below 100 nm and the zeta potential
from neutral to -10 mV has been reported to exhibit the capability to penetrate across
mucus layer 91. Together with the results of Chapter 3 on Calu-3 monolayer which
exhibits mucus layer, it can be inferred that the permeation enhancement of the developed
SEN containing FAME on insulin is not affected by the mucus layer presented in the
nasal cavity.
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4.5 Conclusion
SEN containing G8/10MD could significantly enhance insulin absorption through
intranasal delivery, which was dependent on the concentration of the preconcentrate in
the SEN. The SEN containing G8/10MD (from 5-20% preconcentrate) did not cause
toxicity on nasal epithelium
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Figure 20 Blood glucose levels (% of initial) following s.c. (1 IU/kg) and i.n. (3 IU/kg)
administration of insulin to streptozotocin-induced diabetic rats. (■) s.c. insulin solution;
(△) i.n. insulin in 20SEN; (✕) i.n. insulin in 10SEN; (▲) i.n. insulin in 5SEN; (○) i.n.
insulin solution; (●) i.n. insulin in 1% SLS solution; and (□) i.n. PBS (mean ± SEM; n=34).
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Figure 21 Plasma insulin-time profiles following s.c. (1 IU/kg) and i.n. (3 IU/kg)
administration of insulin formulations to streptozotocin-induced diabetic rats. (■) s.c.
insulin solution; (△) i.n. insulin in 20SEN; (✕) i.n. insulin in 10SEN; (▲) i.n. insulin in
5SEN; (○) i.n. insulin solution; (●) i.n. insulin in 1% SLS solution; and (□) i.n. PBS
(mean ± SEM; n=3-4).
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Table 14 Pharmacokinetic and pharmacodynamic parameters
Treatment
group

Cmax
(µIU/mL)

Tmax
(min)

AAC0-240min
(%Glucose
reduction*h)

AUC0-240min
(µIU*h/mL)

Relative
PA (%)

Relative
BA (%)

SC

68.5 ± 31.3

36.7 ±
16.4

133.6 ± 8.5

82.8 ± 62.5

100

100

SLS

316.6 ±
49.2*,***,##,###

5.0 ±
0.0

135.8 ± 35.7

59.9 ± 8.8

33.9 ±
8.9*

24.1 ±
3.6*

20SEN

247.2 ±
12.2*,***,##,###

12.5 ±
2.5

318.7 ± 37.8

94.1 ± 18.8

79.5 ±
9.4*,**

37.9 ±
7.6*,###

10SEN

101.3 ±
8.0*,###

8.3 ±
3.3

233.9 ± 30.9

48.0 ± 13.4

58.4 ±
7.7*

19.3 ±
5.4*

5SEN

53.2 ± 17.6

5.0 ±
0.0

168.5 ± 52.3

21.8 ± 15.8

42.0 ±
13.0*

8.8 ± 6.4

Insulin
solution

13.5 ± 6.7

15.0 ±
0.0

5.44 ± 24.7

10.0 ± 4.8

1.4 ± 6.1

4.0 ± 1.9

PBS

N/A

N/A

0.0 ± 25.2

N/A

0.0 ± 6.3

N/A

Each value represents the mean ± SEM (n=3-4); SC dose = 1 IU/Kg; treatment 3 IU/Kg
Cmax: maximum insulin concentration; Tmax: time to reach Cmax; AAC: area above the glucosetime curve; AUC: area under the insulin-time curve; PA: relative pharmacological availability
compared with s.c; BA: relative bioavailability compared with s.c.
*: Significantly higher than insulin solution; **: Significantly higher than SLS; ***: Significantly
higher than S.C.; # Significantly higher than 20SEN; ##: Significantly higher than 10SEN; ###:
Significantly higher than 5SEN (p<0.05)
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Figure 22 Photomicrographs of nasal epithelium in rat nasal cavities (section II)
following intranasal administration of (A) insulin solution; (B) insulin in 10SEN; (C)
insulin in 20SEN; and (D) insulin in 1% SLS solution (positive control). S: Septum; OE:
Olfactory Epithelium; RE: Respiratory Epithelium; NC: Nasal Cavity; L-NC: Left Nasal
Cavity; R-NC: Right Nasal Cavity; and Arrow indicates damaged epithelium.
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Figure 23 Comparison of olfactory epithelium in rat nasal cavities following intranasal
administration of (A) insulin solution; (B) insulin in 10SEN; (C) insulin in 20SEN; and
(D) insulin in 1% SLS solution (positive control). L-NC: Left Nasal Cavity; R-NC: Right
Nasal Cavity; and Arrow indicates damaged epithelium.
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Figure 24 Comparison of respiratory epithelium in rat nasal cavities following intranasal
administration of (A) insulin solution; (B) insulin in 10SEN; (C) insulin in 20SEN; and
(D) insulin in 1% SLS solution (positive control). L-NC: Left Nasal Cavity; R-NC: Right
Nasal Cavity; and Arrow indicates damaged epithelium.
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CHAPTER 5
SUMMARY OF THE STUDY AND CONCLUSION
5.1. Summary of The Study
The objective of the present study is to investigate the permeation enhancing
property and safety of SEN, particularly the fatty acid esters (FAEs) when formulated in
SEN, and use these findings to enhance insulin absorption through the nasal route.
Chapter 1 was to identify the factors affecting cytotoxicity and permeation
enhancement of SEN on Madin-Darby Canine Kidney (MDCK) cells, a widely used
paracellular model. The twenty-six FAEs commonly used in SEN were investigated. The
results demonstrate that, among the FAEs (mono-, di-, and triesters), the fatty acid
monoester (FAME) is the main excipient causing concentration-dependent cytotoxicity
and opening of tight junction. When FAME was formulated in SEN, the cytotoxic of
FAME was reduced with the presence of triglycerides, the increase in droplet size, and
the higher intermolecular interaction within lipid droplets. Therefore, four FAMEs
including G8/10MD, G18:1M, G18:2MD and PEG8/10MD were selected to formulate
SEN with triglyceride and further evaluated for their capability to enhance insulin across
the opened tight junctions in cell culture study in Chapter 2.
Chapter 2 was to evaluate the efficacy and toxicity of the developed SEN for the
transport of insulin across cell monolayer in vitro. The coadministration of insulin in the
aqueous phase of SENs containing G8/10MD, G18:2MD, PEG8/10MD could
significantly (p<0.05) enhance the transport of insulin across the human airway epithelial
cell monolayer (Calu-3). The SEN containing G8/10MD at non-toxic concentration
showed the highest permeation-enhancing effect on insulin as compared to the other
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FAMEs. The SEN containing G8/10MD enhance the transport of insulin by
compromising the tight junctions, and the tight junction integrity was recovered after 12
hours. The co-administered of insulin with SEN containing G8/10MD can prevent the
fibril formation of insulin. Therefore, SEN containing G8/10MD was selected to further
evaluate in ex vivo and in vivo studies in Chapter 3 and 4, respectively.
Chapter 3 was to investigate the efficacy and toxicity of the developed SEN for
the transport of insulin across bovine nasal mucosa ex vivo. The 2-h transport of insulin
across the nasal mucosa from both anterior and posterior regions was enhanced by
20SEN (20% of preconcentrate), while the 10SEN (10% of preconcentrate) did not
enhance the transport of insulin. The 20SEN caused minimum nasociliotoxicity on the
bovine nasal mucosa, while no toxicity was observed with the 10SEN. Therefore, 20SEN
was used as the highest concentration in the further in vivo study.
Chapter 4 was to study the efficacy and toxicity of the developed SEN for i.n.
delivery of insulin in streptozotocin-induced diabetic rats. As compared to s.c. injection
of insulin solution, the relative PA achieved by 20SEN, 10SEN, and 5SEN were 57-, 42and 30-fold higher than the solution form (1.4 ± 6.1%), respectively. The relative PA by
20SEN was also significantly (p<0.05) higher than that by the SLS solution (33.9 ±
8.9%). The 20SEN, 10SEN and 5SEN also increased the relative BA by 8.5-, 3.8-, and
1.2-fold higher than that by the solution form, respectively. The relative BA of i.n. insulin
in 20SEN was also significantly higher (p<0.05) than insulin in 5SEN. Both
pharmacokinetic and pharmacodynamic results showed that SEN containing G8/10MD
could significantly (p<0.05) enhance the insulin absorption through intranasal delivery,
which was dependent on the concentration of the preconcentrate in the SEN. The SEN
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containing G8/10MD (from 5-20% preconcentrate) did not cause toxicity on the nasal
epithelium.
In conclusion, the factors affecting cytotoxicity and permeation enhancement of
SEN were elucidated. The coadministration of insulin in the aqueous phase of SEN
containing FAMEs was verified for the efficacy of the transport of insulin across cell
monolayer, in vitro. SEN containing G8/10MD was also verified for their safety and the
capability to enhance insulin absorption across bovine nasal mucosa, ex vivo, and
streptozotocin-induced diabetic rats, in vivo.

5.2. Conclusion
Self-emulsified nanoemulsion (SEN) containing medium-chain monoglyceride
has the potential to deliver insulin across the nasal route.
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